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ABSTRACT OF DISSERTATION 
 
 
THE ROLE OF THE NR4A ORPHAN NUCLEAR RECEPTOR NOR1 IN VASCULAR 
CELLS AND ATHEROSCLEROSIS 
 
The neuron-derived orphan receptor 1 (NOR1) belongs to the NR4A nuclear 
receptor subfamily. As an immediate early response gene, NOR1 is rapidly induced by a 
broad spectrum of physiological and pathological signals. Functional studies demonstrate 
NOR1 as a constitutively active ligand-independent nuclear receptor whose 
transcriptional activity is dependent on both expression level and posttranslational 
modifications. To date, an increasing number of studies have demonstrated a pivotal role 
of NOR1 in the transcriptional control of metabolism and the development of 
cardiovascular diseases. 
In this dissertation, we demonstrate NOR1 expression in endothelial cells and 
sub-endothelial cells of human atherosclerotic lesions. In response to inflammatory 
stimuli, NOR1 expression is rapidly induced in endothelial cells through an 
NF-κB-dependent signaling pathway. Functional studies reveal that NOR1 increases 
monocyte adhesion by inducing the expression of adhesion molecules VCAM-1 and 
ICAM-1 in endothelial cells. Transient transfection and chromatin immunoprecipitation 
assays identify VCAM-1 as a bona fide NOR1 target gene in endothelial cells. Finally, 
we demonstrate that NOR1-deficiency reduces hypercholesterolemia-induced 
atherosclerosis formation in apoE-/- mice by decreasing the macrophage content of the 
lesion.  
In smooth muscle cells (SMC), NOR1 was previously established as a cAMP 
response element binding protein (CREB) target gene in response to platelet-derived 
growth factor (PDGF) stimulation. CREB phosphorylation and subsequent binding of 
phosphorylated CREB to the NOR1 promoter play a critical role in inducing NOR1 
expression. In this dissertation, we further demonstrate that histone deacetylase (HDAC) 
inhibition potentiates and sustains PDGF-induced NOR1 mRNA and protein expression 
 
 
in SMC. This augmented NOR1 expression is associated with increased phosphorylation 
of CREB, recruitment of phosphorylated CREB to the NOR1 promoter, and 
trans-activation of the NOR1 promoter. Additionally, HDAC inhibition also increases 
NOR1 protein half-life in SMC.  
Collectively, these findings identify a novel pathway in endothelial cells underlying 
monocyte adhesion and expand our knowledge of the epigenetic mechanisms 
orchestrating NOR1 expression in SMC. Finally, we establish a previously unrecognized 
atherogenic role of NOR1 in positively regulating monocyte recruitment to the vascular 
wall. 
KEYWORDS: nuclear receptor; endothelial cells; atherosclerosis; smooth muscle cells; 
epigenetic mechanism 
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Chapter one: Introduction 
1.1. Background 
1.1.1. Introduction on atherosclerosis 
Atherosclerosis is a chronic inflammatory and proliferative disease, in which immune 
mechanisms interact with arterial risk factors to initiate early fatty streaks1, 2. Continued 
lesion progression results in a mature lipid-enriched necrotic core surrounded by a cap of 
activated smooth muscle cells1, 3. In this process, endothelial cells, smooth muscle cells 
and monocyte-derived macrophages constitute the primary cell types responsible for 
atherosclerosis development1, 2. 
The endothelium, a barrier between circulating blood and tissues, does not support 
leukocyte binding under normal conditions2, 4. However, at the early stage of 
atherosclerosis, endothelial cells undergo inflammatory activation/dysfunction in response 
to atherogenic factors, such as inflammatory cytokines and hypercholesterolemia5, 6. 
Increased expression of chemokines and adhesion molecules leads to monocyte 
recruitment into the arterial wall, which is the key initial step for atherosclerotic lesion 
formation1. Numerous studies revealed that monocyte homing is a tightly regulated 
process, including initial rolling along the endothelium, triggering adhesion, strengthening 
adhesion and finally transmigrating across the endothelium. Many chemokines and 
adhesion molecules are involved in this process, including vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), platelet endothelial 
cell adhesion molecule-1 (PECAM-1), selectins and integrins7. In vivo mouse model 
studies demonstrate that reduced expression of adhesion molecules or chemokines protects 
against the development of atherosclerosis. For example, the deficiency of monocyte 
chemoattractant protein-1 (MCP-1) reduces macrophage recruitment and atherosclerotic 
lesion formation in low density lipoprotein receptor (LDLR)-deficient mice and human 
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apolipoprotein (apo) B transgenic mice8, 9. Consistently, deletion of MCP-1 receptor CCR2 
markedly decreases aortic macrophage accumulation and lesion formation in apoE 
knockout mice10. While whole body VCAM-1 deficient mice are not viable, studies using 
different knockdown strategies demonstrate a VCAM-1 gene dosage-dependent effect on 
atherosclerosis development11, 12. In addition, ICAM-1 deficiency has been shown to 
protect against atherosclerosis formation in apoE knockout mice13. 
The continuous retention of atherogenic lipoproteins, recruitment of monocytes, and 
lipid uptake by monocyte-derived macrophages promote fatty streak formation1, 2. The role 
of macrophage accumulation in promoting lesion initiation and progression was initially 
demonstrated by the observation that hypercholesterolemic mice become resistant to 
atherosclerosis when they are bred to macrophage-deficient mice14. Recent advances in 
this area demonstrate that monocytes are highly heterogeneous and each subtype plays 
distinct roles in atherosclerosis development15. CCR2+CX3CR1+Ly-6Chi and 
CCR2–CX3CR1++Ly-6Clo monocytes constitute two major subtypes, and data suggest that 
these monocytes utilize different receptors to infiltrate into the vascular wall16. While 
CCR2+ monocytes are more efficiently recruited into the sub-endothelial space, CCR2- 
monocytes exhibit a higher potential in developing into plaque cells16. In addition to 
monocytes, other leukocyte subsets have also been observed in atherosclerotic lesions at 
various stages17, such as neutrophils18, mast cells19, dendritic cells20, 21 and T 
lymphocytes17. Although mostly found in the arterial adventitia, B lymphocytes are 
thought to confer a protective immunity during atherogenesis17. 
Further lesion progression advances by continued macrophage accumulation and a 
broad range of inflammatory responses1, 2. Recently, emerging evidence recapitulates the 
concept of inflammation resolution, which was considered only as a passive process. 
However, recent findings suggest that this process in fact represents a large number of 
actively regulated anti-inflammatory responses22, 23. Inflammation resolution in 
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atherosclerotic lesions can be achieved through several steps, including prevention of 
macrophage recruitment, promotion of anti-inflammatory cytokine expression, and 
efficient efferocytosis (clearance of apoptotic inflammatory cells)22, 23.  
The observation that increased macrophage apoptosis reduces early lesion formation 
is indicative of effective clearance of apoptotic cells in early atherogenesis24. On the 
contrary, another study demonstrates that phagocytosis of apoptotic cells is impaired in 
advanced atherosclerotic lesions25. These findings point to a protective role of 
efferocytosis in early atherogenesis. The maintenance of efficient efferocytosis in later 
stages may provide a novel strategy to attenuate atherosclerosis progression. Given the 
important role of macrophages in efferocytosis23, these findings elicit an interesting 
concept that macrophages promote atherogenesis by producing inflammatory cytokines, 
while play a protective role through the clearance of apoptotic cells. Some evidence has 
implied that macrophage phenotype can be triggered to switch between classically (M1) 
and alternatively (M2) activated macrophages26. An increasing number of studies suggest 
that M2 macrophages are less inflammatory and have a greater phagocytic capacity27. 
Therefore, future studies on monocyte/macrophage subtypes may explain the 
discrepancies observed in macrophages. 
Progression of early fatty streaks into complex atherosclerotic lesions is 
accompanied by SMC activation, migration and proliferation1, 2. Vascular SMCs constitute 
the major component of arteries and maintain a quiescent contractile phenotype in normal 
physiological conditions. In atherosclerotic lesions, inflammatory cytokines and mitogens 
trigger SMC migration into the arterial intima. Intimal SMCs undergo a phenotypic 
transition which is associated with a higher proliferation rate and greater synthesis 
capacity28. In addition, intimal SMCs take up lipids and secrete extracellular matrix 
proteins1, 2. A key role of these intimal SMCs is to form a fibrous cap under the endothelial 
cell layer, stabilizing lesions and preventing the necrotic lipid core from interacting with 
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blood1, 2. However, the continuous proliferation of SMCs and formation of extracellular 
matrix further promote lipoprotein retention and contribute to the narrowing of the vessel 
lumen1, 2. Another element of advanced atheroma is increased secretion and activation of 
matrix metalloproteinases (MMPs). MMPs function to degrade extracellular matrix, 
ultimately resulting in a thinner and more fragile fibrous cap prone to rupture1-3. While 
plaque rupture and thrombosis usually lead to acute cardiovascular diseases such as 
myocardial infarction and stroke, massive SMC proliferation plays a major role in the 
failure of occlusive vascular disease interventions, such as in-stent restenosis.29 
1.1.2. Introduction on epigenetics 
It was proposed by Conrad Waddington in the 1950s that “An epigenetic trait is a 
stably heritable phenotype resulting from changes in a chromosome without alterations in 
the DNA sequence”30. This original definition of epigenetics emphasizes the heritability of 
a phenotype through cell divisions. Intensive studies have revealed that cellular responses 
to physiological/pathological signals involve a large number of transient chromatin 
modifications. In fact, these chromatin changes in response to environmental cues exactly 
reflect the ability of a cell to remember its past state31. Therefore, a broader definition of 
epigenetics has evolved to include these transient events happening to the chromosome.  
Factors involved in epigenetic regulation include DNA methylation, histone 
modifications, transcription factors, non-coding RNAs, nucleosome position, and 3D 
organization of genes in the nucleus31, 32.  There are a variety of histone post-translational 
modifications (PTM) which can be categorized into histone lysine acetylation, methylation, 
ubiquitinization and sumoylation, serine/threonine phosphorylation, arginine methylation 
and proline isomerization33. DNA methylation and histone PTM are most well 
characterized epigenetic markers, which can be read and translated into signals dictating 
gene activation and repression33, 34. For instance, acetylation of histone H4 on lysine 16 
(AcH4-K16) is associated with increased gene expression35 and has been shown to disrupt 
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higher chromatin structure in nucleosomal arrays36. This example represents a direct 
mechanism in which chromatin modifications activate gene transcription by increasing 
DNA accessibility to transcription factors33. Another mechanism by which chromatin 
modifications indirectly influence gene transcription involves the recruitment of chromatin 
binding proteins33. For example, acetylated histone H3 and H4 peptides only function to 
recruit other bromodomain-containing transcription co-activators whose acetyl-transferase 
activity is required for gene activation37. 
Both DNA methylation and histone PTM are reversible33. The addition and removal 
of these chromatin modifications are carried out by specific enzymes33. For example, 
histone acetyl-transferases (HAT) add acetyl-groups to lysine residues while histone 
deacetylases (HDAC) remove the acetylation33, 38. Gcn5 N-acetyltransferases (GNAT) and 
MYST HATs are the two predominant families of HAT. A number of transcription 
co-activators such as p300/CBP possess intrinsic acetyl-transferase activity and are 
categorized as HAT39. In addition, eighteen human HDACs have been identified with 
different substrate selectivity38. Similarly, all other chromatin modification enzymes 
consist of a large number of family members40, 41. Therefore, the timely and sequential 
actions of various chromatin modification enzymes are essential for orchestrating gene 
expression. 
Cardiovascular disease, which involves dysregulated gene expression in the 
cardiovascular system 116, is one of the leading causes of death in the world1-3. Since every 
single cell in the body is subjected to epigenetic regulation, understanding the underlying 
mechanisms will provide further insight on the development, physiology and disease of 
cardiovascular system42.   
1.1.3. Introduction on NR4A orphan nuclear receptors 
This part is published, with Yue Zhao as first author, in two review articles 
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“Arterioscler Thromb Vasc Biol. 2010 Aug;30:1535; Copyright © 2010 American Heart 
Association” and “Drug Discov Today Dis Mech. 2009;6:e43; Copyright © 2009 Elsevier 
Ltd.”.  
1.1.3.1. Molecular biology of NR4A orphan nuclear receptors 
Nuclear receptors (NR) share a common structure consisting of a ligand-independent 
AF-1 transactivation domain in the N-terminal region, a highly conserved DNA-binding 
domain (DBD) composed of two zinc fingers recognizing specific DNA sequences, and a 
ligand-binding domain (LBD) that contains a ligand-dependent AF-2 transactivation 
domain in its C-terminal portion (Figure 1.1A)43. NR4A receptors share this common NR 
structure, and the three members reveal a high degree of homology in their genomic 
structure and conservation of their DNA binding domain (degree of conservation > 90%)44. 
However, several lines of evidence indicate that NR4A receptors may represent a distinct 
group of transcription factors that do not function in a classical manner. Mutational 
analysis indicated that NR4A receptors function as constitutively-active receptors whose 
transcriptional activity is independent on the LBD45, 46. Instead, their transcriptional 
activity and co-activator recruitment appear to be dependent on the N-terminal AF-1 
domain46-48, which constitutes a common distinction of ligand-independent transcriptional 
activation by NR49, 50. This initial observation was supported by the finding that the LBD of 
NR4A contains hydrophilic surfaces instead of the classical hydrophobic cleft that 
mediates co-activator recruitment of other NR48. Finally, this unusual structure of the 
NR4A LBD has been recently confirmed by X-ray crystallography demonstrating that the 
Nurr1 LBD contains no cavity as a result of hydrophobic residues in the region normally 
occupied by ligands51. Considering these observations, NR4A receptors are currently 
thought to function as constitutively-active and ligand-independent receptors, whose 
transcriptional activity is primarily dependent on the expression of the receptor and its 
posttranslational modification.  
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NR4A receptors are early immediate response genes, which are induced by a 
pleiotropy of stimuli including growth factors, inflammatory stimuli, cytokines, peptide 
hormones, and cellular stress (Table 1.1)52. Once their expression is induced, NR4A 
receptors activate transcription by binding as monomers or homodimers to canonical DNA 
target sites, the NGFI-B-responsive element (NBRE) consisting of an octanucleotide 
AAAGGTCA motif (Figure 1.1B)53, 54. NR4A homodimers preferentially bind to the 
Nur-responsive element (NurRE), which constitutes an everted repeat of the NBRE-related 
sequence (AAAT(G/A)(C/T)CA) found in the pro-opiomelanocortin (POMC) gene 
promoter55. In addition, Nur77 and Nurr1 (but not NOR1) heterodimerize with RXR and 
activate transcription through a DR-5 element in a 9-cis retinoic acid-dependent manner56, 
57. This heterodimerization of Nurr1 with RXR is isotype-specific since Nurr1 interacts 
only with RXRα and RXRγ but not with RXRβ 58. Furthermore, different NR4A receptors 
can form heterodimers to synergistically activate transcription59. While it was initially 
thought that NR4A receptors only activate genes, a recent study has provided first evidence 
that Nurr1 can also repress inflammatory gene promoters by recruiting co-repressor 
complexes60.  
In addition to the rapid expression as early response genes, the transcriptional activity 
of NR4A receptors is regulated by posttranslational modification. All three NR4A 
receptors are phosphorylated at serine residues in response to growth factor-dependent 
activation of various kinases, including MAPK, PI3K, Akt, JNK, and RSK58, 61-64. For 
example, Nur77 is phosphorylated at Ser-350 and Ser-354 within the DNA binding domain, 
which inhibits the trans-activation activity65, 66. Furthermore, phosphorylation of Nur77 at 
Ser-105 induces nuclear export of the Nur77/RXR heterodimer complex67, providing an 
additional mechanism by which phosphorylation may inhibit the transcriptional activity of 
Nur77. In addition to phosphorylation, all NR4A receptors contain sumoylation consensus 
sites, and sumoylation of Nurr1 induces or inhibits the transcriptional activity in a 
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sumoylation site-specific manner68. Although still in its infancy, these posttranslational 
modifications regulate the transcriptional activity and may represent a major mode of the 
control of gene expression by NR4A receptors.  
1.1.3.2. NR4A nuclear receptors in metabolism and energy balance 
Carbohydrate metabolism  
All three NR4A receptors are potently induced in the liver in response to physiological 
stimuli, including fasting and glucagon stimulation (Figure 1.2)69, 70. Furthermore, hepatic 
NR4A receptor expression is increased in diabetic mice as a model of pathologic 
gluconeogenesis69. Functional studies further demonstrated that adenoviral 
over-expression of Nur77 increases the expression of genes involved in gluconeogenesis 
and stimulates hepatic glucose production in mice69. Interestingly, Nur77 over-expression 
induces several gluconeogenic genes including G6pc, Fbp1 and Fbp2, and enolase 3, 
which all contain NBRE consensus sites in their promoters69. Therefore, this study has 
provided the first experimental evidence that NR4A receptors regulate gluconeogenesis 
and may serve to link hormonal stimulation to downstream metabolic gene expression. 
In skeletal muscle, NR4A receptors are induced by growth factors, β-adrenergic 
signaling, and endurance exercise71-74. Maxwell et al. first demonstrated that knock-down 
of Nur77 in muscle cells results in decreased lipolysis and expression of genes regulating 
energy expenditure and lipid homeostasis, including AMP-activated protein kinase, UCP3, 
Glut4, CD36, adiponectin receptor 2, and caveolin-372. Conversely, Cao et al. reported that 
overexpression of Nur77 in C2C12 muscle cells increases the expression of genes involved 
in glucose and glycogen metabolism while Nur77 deficiency in mice reduces the 
expression of genes involved in skeletal muscle glucose utilization in vivo75. Consistent 
with this role of Nur77 to promote glucose utilization was the observation that 
Nur77-deficient mice develop skeletal muscle insulin resistance when fed a high fat diet 
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due to altered insulin signaling and reduced GLUT4 expression76. Although glucose 
metabolism has not been studied in NOR1-deficient mice, knock-down of NOR1 in 
skeletal muscle cells attenuates the expression of genes that control fatty acid oxidation and 
pyruvate use (i.e. PGC-1α, PGC-1β, lipin-1α, PDP1r and PDP1c) indicating that NOR1 
may be necessary for oxidative metabolism77. Finally, NOR1 has recently been 
demonstrated to also promote insulin-stimulated glucose uptake in adipocytes by 
augmenting insulin signaling and GLUT4 translocation78. In concert, these intriguing 
observations point to a key role of NR4A receptors in the transcriptional control of glucose 
homeostasis and oxidative metabolism.  
Lipid metabolism  
Accumulating evidence indicates that NR4A receptors regulate various aspects of 
lipid metabolism. As noted earlier, initial experiments by Maxwell et al. demonstrated that 
Nur77 promotes lipolysis in muscle72. Subsequently, Pols et al. revealed that Nur77 
modulates plasma lipoprotein profiles and hepatic lipid metabolism in mice79. In this study, 
adenoviral-mediated over-expression of Nur77 increased plasma LDL cholesterol and 
decreased HDL cholesterol while reducing hepatic triglyceride levels, which was thought 
to be due to a repression of the lipogenic transcription factor SREBP1c79. Consistent with 
these data, Chao et al. noted hepatic steatosis and increased SREBP1c expression in 
Nur77-deficient mice fed a high fat diet76. However, since Nur77 did not directly affect 
SREBP1c activity in reporter assays, the authors concluded that the hepatic steatosis in 
Nur77-deficient mice was likely secondary to the lipogenic effect of hyperinsulinemia76.  
In 3T3-L1 preadipocytes, NR4A receptors expression is induced during adipogenesis 
and initiating of the differentiation program80, 81. Initial studies using siRNA approaches 
and over-expression of a Nur77 mutant lacking the N-terminal AF-1 trans-activation 
domain indicated that Nur77 is not required for adipocyte differentiation82. However, a 
functional role for NR4A receptors in adipogenesis was suggested by two recent in vitro 
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studies, which have demonstrated that constitutive NR4A receptor expression in 3T3-L1 
preadipocytes inhibits adipocyte differentiation83, 84. One of the mechanisms proposed for 
this negative regulation of adipogenesis by NR4A receptors has been the inhibition of the 
mitotic clonal expansion of preadipocytes83. However, considering that the initial mitotic 
expansion step is primarily a prerequisite for 3T3-L1 preadipocyte differentiation, further 
studies seem required and there are likely additional mechanisms involved by which NR4A 
receptors inhibit adipogenesis. These may include a direct regulation of target genes 
affecting adipogenesis, including extracellular matrix genes83. In addition, NR4A receptors 
may cross-talk with adipogenic signalling and transcriptional programs, particularly since 
Nurr1 and Nur77 have been reported to interact with Wnt signaling pathways or the 
glucocorticoid receptor, which both play important roles in adipogenesis85-87.  
Energy homeostasis 
Brown adipose tissue plays a key role in energy balance and is the primary organ 
involved in thermogenesis through uncoupling of mitochondrial respiration by the action 
of uncoupling proteins (UCP). Early studies have demonstrated that Nur77 expression is 
highly induced in response to β-adrenergic stimulation of brown adipocytes while 
transcript levels of all three NR4A receptors are induced during cold-exposure88, 89. 
Kanzleiter et al. demonstrated a repressive effect of Nur77 on the UCP-1 promoter in 
brown adipocytes, which was likely indirect since Nur77 did not directly interact with the 
UCP-1 promoter88. Despite this repression of UCP-1, nonshivering thermogenesis was not 
affected by Nurr77 deficiency in mice88. In contrast, Kumar et al. observed that NOR1 
transcriptionally up-regulates UCP-1 expression by binding to an NBRE site on the UCP-1 
promoter89. Furthermore, over-expression of a Nur77 mutant lacking the N-terminal AF-1 
trans-activation domain prevented UCP-1 transcription induced by β-adrenergic 
signaling89. The reasons underlying these seemingly conflicting two studies remain unclear 
but are likely due to a differential regulation of UCP-1 by Nur77 and NOR1. Moreover, 
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NR4A receptors may affect the central regulation of energy homeostasis since injection of 
NOR1 siRNA into the third cerebral ventricle significantly suppresses food intake and 
body weight in mice90. In concert, these intriguing studies characterize NR4A receptors as 
important regulators of energy balance and food intake, although the underlying 
mechanisms remain elusive and warrant further studies in gene-targeted mice. 
1.1.3.3. NR4A nuclear receptors in vascular biology 
An increasing number of studies have demonstrated that all three members of the 
NR4A subfamily are expressed in the developing neointima and in advanced 
atherosclerotic lesions91-97.  Moreover, accumulating evidence indicates that NR4A 
receptors constitute important transcription factors in the control of vascular gene 
expression and play critical roles in essentially all aspects of vascular remodeling, 
including cell viability, proliferation, and inflammation (Figure 1.3). In the following 
section, we will briefly summarize these studies pointing to a previously unrecognized 
function of NR4A receptors in vascular biology.   
Cell viability and proliferation  
 Endothelial cell injury followed by the expression of adhesion molecules and the 
subsequent recruitment of circulating monocytes constitute critical events for the initiation 
of atherosclerosis98. All three NR4A receptors are potently induced by a variety of 
pro-atherogenic stimuli in endothelial cells, including atherogenic lipoproteins, 
inflammatory cytokines, growth factors, and hypoxia (Figure 1.3)92, 99-105. The 
transcriptional mechanisms governing this inducible expression have been primarily 
studied in the context of growth factor and hypoxia-induced NOR1 expression. While the 
former mechanisms involve a cAMP response element binding protein (CREB)-dependent 
activation of the NOR1 promoter101, 105, NOR1 expression in response to hypoxia is 
dependent on hypoxia-inducible factor 1 (HIF-1) binding to a hypoxia response element in 
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the promoter103. Arkenbout et al. performed the first functional experiments in endothelial 
cells and demonstrated that adenoviral over-expression of Nur77 inhibits proliferation of 
this cell type by up-regulating p27Kip1 and down-regulating cyclin A92. However, the role 
of Nur77 for endothelial cell proliferation remains controversial since Zeng et al. reported 
that Nur77 induces proliferation and cell cycle gene expression102. Moreover, this report 
noted that angiogenesis is induced by over-expression of Nur77 and decreased in Nur77-/- 
mice102. With respect to the sibling NOR1, Rius et al. identified a mitogenic role for this 
receptor by demonstrating that antisense oligonucleotides against NOR1 inhibit 
endothelial cell growth and wound repair after injury101. Consistent with these 
observations, NOR1 has recently been characterized as a pro-survival gene in endothelial 
cells exposed to hypoxia by inducing the expression of cellular inhibitor of apoptosis 
protein 2103. Collectively, these studies establish a role for Nur77 and NOR1 in regulating 
endothelial cell survival and proliferation; however, little is known about the 
transcriptional target genes and molecular mechanisms. At present, only two direct NR4A 
target genes have been identified in endothelial cells. Gruber et al. characterized PAI-1 as a 
Nur77 target gene, which is activated by the receptor through direct binding to an NBRE 
site in the promoter99.  In addition, You et al. demonstrated that Nur77 overexpression 
prevents NF-κB nuclear translocation in endothelial cells by enhancing the expression of 
IκBα, which is mediated through a direct trans-activation of a NBRE site in the IκBα 
promoter104. Interestingly, the functional relevance of Nur77-dependent IκBα expression 
was confirmed by the finding that Nur77 inhibited the expression of VCAM-1 and 
ICAM-1 in endothelial cells104.  
 Similarly as in endothelial cells, NR4A receptor expression is rapidly induced in 
response to atherogenic stimulation of smooth muscle cells (SMC), including lipoproteins, 
cyclic stretch, and mitogenic stimuli91, 93-95, 106. The transcriptional induction of NOR1 in 
SMC is mediated through mitogen-induced CREB binding to CRE sites in the NOR1 
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promoter and can be pharmacologically inhibited by simvastatin93, 94, 106, 107. Consistent 
with the earlier described growth-inhibitory function of Nur77 in endothelial cells, Nur77 
over-expression inhibits SMC proliferation in vitro by stabilizing of p27Kip191, 108 and 
reduces neointima formation in vivo91. Interestingly, data from the same group has further 
recently suggested that SMC-specific over-expression of Nur77 inhibits pathological 
outward remodeling in response to carotid artery ligation, which was associated with 
decreased macrophage accumulation and MMP expression109. While these studies clearly 
indicate that Nur77 prevents SMC proliferation, NOR1 has been reported to act mitogenic 
suggesting a function that is distinct from that of Nur77. A proliferative role of NOR1 was 
first reported by Martínez-González et al. using antisense NOR1 oligonucleotides93. 
Consistent with these initial observations, data from our group has demonstrated a 
proliferative defect and an increased propensity for apoptosis in SMC isolated from 
NOR1-deficient mice94, 95. In vivo, the proliferative response and neointima formation 
following endovascular femoral artery guide wire injury was decreased in NOR1-deficient 
mice95. At a molecular level, this mitogenic activity of NOR1 was at least in part mediated 
by a trans-activation of a canonical NBRE site in the cyclin D1 promoter, characterizing 
cyclin D1 as a bona fide NOR1 target gene in SMC95. Furthermore, DNA microarray 
profiling revealed a lower expression of NOR1 in elongated SMC while NOR1 
knock-down suppressed DNA synthesis, further supporting the mitogenic function of 
NOR1 and pointing to a potential role of NOR1 in regulating cell shape110. In concert, these 
studies establish not only an important but also distinct role for Nur77 and NOR1 in the 
control of vascular cell proliferation and remodeling. Continued investigation will be 
required to define the transcriptional target genes and the molecular basis underlying the 
differential function of NOR1 and Nur77 in SMC biology. 
Inflammation  
The first evidence linking NR4A expression with inflammatory signaling was 
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reported by Woronicz et al. and Liu et al., who noted that Nur77 is induced in apoptotic 
T-cells and that inhibition of Nur77 function prevented apoptosis111, 112. However, mice 
deficient in Nur77 exhibit unimpaired T-cell apoptosis, and functional redundancy of 
Nur77 and NOR1 in T-cell apoptosis has been suggested113, 114. Similarly to T-cells, Nur77 
expression is increased in apoptotic macrophages and, in contrast to the experiments 
performed in T-cells, peritoneal macrophages isolated from Nur77-deficient mice reveal a 
phenotype of reduced cell death115. In response to inflammatory activation, all three NR4A 
receptors are potently induced in macrophages96, 97. This inducible expression of NR4A 
receptors in macrophages depends on the activation of NF-κB signaling, as exemplified by 
the recruitment of NF-κB to response elements in the Nur77 promoter96. Functional studies 
have indicated that NR4A receptors both activate and repress inflammatory genes in 
macrophages60, 97, 116. An initial microarray analysis by Pei et al. discovered that NR4A 
overexpression in macrophages induces proinflammatory gene expression116. Interestingly, 
among the identified direct Nur77 target genes was the inducible kinase IKKi/IKKepsilon, 
which functions as a NF-κB activating kinase, providing a potential mechanism for the 
activation of inflammatory gene expression by Nur77 in macrophages116. In contrast to 
these studies, Bonta et al. revealed that lentiviral over-expression of each NR4A member 
reduces certain inflammatory genes (i.e. IL-1β, IL-6, IL-8, MIP1α and 1β and MCP-1) and 
the uptake of oxidized LDL97. Finally, a recent study by Saijo et al. identified that Nurr1 
transcriptionally represses the inflammatory genes TNFα, iNOS, and IL-1β in microglia 
and the murine RAW264.7 cell line60. This trans-repression was mediated through a 
Nurr1-dependent recruitment of the co-repressor for element-1-silencing transcription 
factor (CoREST) complex to the target promoter and the subsequent clearance of NF-κB60. 
While these studies indicate that NR4A receptors function as important transcriptional 
regulators of inflammatory gene expression, further in vivo evidence using animal models 
deficient for either of the NR4A receptors seems required, particularly with respect to the 
development of atherosclerosis. 
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1.2. General hypothesis and specific aims 
In conclusion, emerging evidence indicates that NR4A nuclear receptors have 
multifaceted, even contradictory, effects in vascular cells and macrophages. The induction 
of NOR1 in endothelial cells and smooth muscle cells elicit a proliferative effect on cell 
growth. Whereas accelerated endothelial cell growth benefits revascularization after 
vascular injury, increased smooth muscle cell proliferation leads to intimal thickening and 
ultimately vascular occlusion. Additionally, the role of NOR1 in endothelial cell activation 
and inflammatory signaling still needs to be investigated. In macrophages, recent studies 
indicate that NOR1 can be either pro- or anti-inflammatory dependent upon the choice of 
target genes and specific assays. Therefore, it is intriguing and necessary to further explore 
the functions of NOR1 in vascular cells and to identify the net effect of NOR1 on 
atherosclerosis development.  
At the beginning of this study, we found that NOR1 expression is induced by 
inflammatory stimuli in endothelial cells and increases adhesion molecule expression. In 
addition, it was reported by our group that mitogen induced NOR1 expression promotes 
vascular smooth muscle cell proliferation. Based on these findings, it was hypothesized 
that NOR1 plays an atherogenic role in atherosclerosis development. In order to test 
this hypothesis, two specific aims were proposed: 
Specific aim I. To investigate how transcriptional induction of NOR1 during 
endothelial cell activation contributes to monocyte recruitment and atherosclerosis 
development. 
Specific aim II. To characterize the epigenetic regulation of NOR1 expression in 
vascular smooth muscle cells. 
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Table 1.1. NR4A orphan nuclear receptors are induced by pleiotropic physiological 
and pathological signals* 
 Stimuli Expression 
locations 
Effects Potential 
partners 
NR4A1 
(Nur77) 
parathyroid 
hormone117 
bone bone metabolism  
Palmitate, 
oleate118 
pancreatic 
beta-cells 
beta-cell adaptation to 
hyperlipidemia 
 
nerve growth 
factor, membrane 
depolarization119 
PC12 cells neuron survival during 
development 
 
antipsychotic 
drugs: raclopride, 
olanzapine120 
CA1 region of 
the 
hippocampus 
antipsychotic drug 
effects in the central 
nervous system 
 
9-cis retinoic 
acid56 
human chorion 
carcinoma 
JEG-3 cells 
crosstalk between 
retinoid and growth 
factor signaling 
pathways 
Retinoid X 
Receptor 
(RXR) 
T-cell receptor 
activation114 
thymocytes thymocyte apoptosis  
deficiency of 
Nur77 and 
NOR1121, 122 
hematopoietic 
stem cells, 
myeloid 
progenitors 
mixed 
myelodysplastic/myelo
proliferative 
neoplasms, acute 
myeloid leukemia 
 
NR4A2 
(Nurr1) 
Nurr1 deficiency 
123 
mouse embryo 
midbrain 
midbrain dopaminergic 
cell differentiation 
 
antipsychotic 
drugs: clozapine; 
fluphenazine; 
haloperidol; 
risperidone;120  
CA1 region of 
the 
hippocampus 
antipsychotic drug 
effects in the central 
nervous system 
 
parathyroid 
hormone124 
bone bone metabolism  
9-cis retinoic 
acid56 
human chorion 
carcinoma 
JEG-3 cells 
crosstalk between 
retinoid and growth 
factor signaling 
pathways 
Retinoid X 
Receptor 
(RXR) 
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Table 1.1. NR4A orphan nuclear receptors are induced by pleiotropic physiological 
and pathological signals* (continued) 
 
 Stimuli Expression 
locations 
Effects Potential 
partners 
NR4A2 
(Nurr1) 
normal Nurr1 
expression125 
hematopoietic 
stem cells 
hematopoietic stem cell 
quiescence 
 
NR4A3 
(NOR1) 
antipsychotic 
drugs: 
risperidone,  
clozapine120 
CA3 region of 
the 
hippocampus 
antipsychotic drug 
effects in the central 
nervous system 
 
NOR1 
deficiency126 
semicircular 
canal during 
early otic 
development 
inner ear defect, partial 
bidirectional circling 
behavior 
 
parathyroid 
hormone127 
osteoblasts crosstalk between 
parathyroid hormone 
and steroid hormone 
receptor signaling 
pathways 
 
T-cell receptor 
activation114 
thymocytes thymocyte apoptosis  
deficiency of 
Nur77 and 
NOR1121, 122 
hematopoietic 
stem cells, 
myeloid 
progenitors 
mixed 
myelodysplastic/myelo
proliferative 
neoplasms, acute 
myeloid leukemia 
 
* The induction of NR4A orphan nuclear receptors in the liver, muscle, adipose tissues, and 
vascular cells is summarized in Figure 1.2 and Figure 1.3. 
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Figure 1.1. Molecular biology of NR4A orphan nuclear receptors 
(A) NR4A nuclear receptors share a conserved molecular structure consisting of an 
N-terminal AF-1 domain, a central DNA-binding domain (DBD), and a C-terminal ligand 
binding domain (LBD) and AF-2 domain. (B) NR4A receptors induce gene expression by 
binding as monomers to the NBRE site and as homodimers or heterodimers to the NurRE 
site in the promoter of their regulated target genes. NurREPOMC represents the binding 
sequence demonstrated in the pro-opiomelanocortin (POMC) promoter, while NurRECON 
represents the NurRE site comprising consensus NBRE sites. Nur77 and Nurr1, but not 
NOR1, heterodimerize with RXR and bind to the direct repeats of nuclear receptor 
binding motif separated by five nucleotides (DR5). 
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Figure 1.2. NR4A receptor function in metabolism and energy balance 
NR4A orphan nuclear receptors are potently induced by physiological and pathological 
stimuli in the liver, muscle and adipose tissues. In these tissues, NR4A orphan receptors 
function as transcriptional regulators of gene expression programs involved in the control 
of glucose homeostasis, lipid metabolism, and energy expenditure (see text for details). 
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Figure 1.3. Expression and function of NR4A receptors in vascular cells 
NR4A orphan nuclear receptors are induced in vascular cells by a variety of stimuli, 
including inflammatory mediators, cytokines, hypoxia, and growth factors. In response to 
these pathophysiological environmental cues, NR4A receptors modulate gene expression 
leading to cell-specific processes (see text for details). 
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Chapter two: Deficiency of the NR4A orphan nuclear receptor NOR1 decreases 
monocyte adhesion and atherosclerosis 
This part is published in “Circ Res. 2010 Aug;107:501; Copyright © 2010 American 
Heart Association”, with Yue Zhao as first author. 
2.1. Synopsis  
The orphan nuclear receptor NOR1 is a member of the evolutionary highly conserved 
and ligand-independent NR4A subfamily of the nuclear hormone receptor superfamily. 
Members of this subfamily have been characterized as early response genes regulating 
essential biological processes including inflammation and proliferation; however the role 
of NOR1 in atherosclerosis remains unknown. In the present study, we demonstrate 
expression of NOR1 in endothelial cells of human atherosclerotic lesions. In response to 
inflammatory stimuli, NOR1 expression is rapidly induced in endothelial cells through a 
NF-κB-dependent trans-activation of the NOR1 promoter. Over-expression of NOR1 in 
human endothelial cells increased the expression of VCAM-1 and ICAM-1 while NOR1 
deficiency altered adhesion molecule expression in response to inflammatory stimuli. 
Transient transfection experiments and chromatin immunoprecipitation assays revealed 
that NOR1 induces VCAM-1 promoter activity by binding to a canonical response element 
for NR4A receptors in the VCAM-1 promoter. Further functional studies confirmed that 
NOR1 mediates monocyte adhesion by inducing VCAM-1 and ICAM-1 expression in 
endothelial cells. Finally, we demonstrate that NOR1-deficiency reduces 
hypercholesterolemia-induced atherosclerosis formation in apoE-/- mice by decreasing the 
macrophage content of the lesion. In concert, these studies identify a novel pathway 
underlying monocyte adhesion and establish that NOR1 serves a previously unrecognized 
atherogenic role in mice by positively regulating monocyte recruitment to the vascular 
wall. 
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2.2. Introduction 
The transcription factor NOR1 (NR4A3) belongs to the highly conserved NR4A 
subfamily of orphan nuclear hormone receptors52, 128. Members of this subgroup are 
classified as early response genes, which are induced by a pleiotropy of stimuli, including 
mitogens and inflammatory signals93, 129. In contrast to other members of the nuclear 
receptor superfamily, NR4A receptors function as constitutively-active and 
ligand-independent transcription factors45, 130. Therefore, the transcriptional activity of 
NR4A receptors is determined by the expression level and by posttranslational 
modifications of the receptor131. NR4A receptors positively regulate target gene expression 
by binding as monomer or homodimer to different variations of the canonical 
5’-A/TAAAGGTCA NGFI-B response element (NBRE)53. In addition, Nur77 (NR4A1) 
and Nurr1 (NR4A2) exhibit transcriptionally distinct mechanisms, as both are able to 
trans-activate target genes as a heterodimer with RXR132. Consistent with the pleiotropic 
stimuli that induce the expression of NR4A receptors, these transcription factors have been 
implicated in regulating key cellular functions, including inflammation, proliferation, and 
cell survival52, 128. 
NOR1 was first cloned from neuronal cells, and its deletion in mice results in 
hippocampal dysgenesis and inner ear defects133, 134. In addition to neurons, NOR1 is 
highly expressed in atherosclerotic lesions93, 94, 135, 136. NOR1 is induced by mitogens in 
smooth muscle cells (SMC) and required for proliferative remodeling following vascular 
injury93-95. In macrophages, NOR1 is induced during inflammation and represses cytokine 
secretion129, 136. Finally, NOR1 expression is increased by vascular endothelial growth 
factor (VEGF) in endothelial cells101. However, the functional role of NOR1 in endothelial 
cells and its contribution to atherosclerosis remain to be investigated.  
In the present study, we provide first evidence that NOR1 plays an essential role in the 
regulation of monocyte adhesion to the endothelium by positively regulating VCAM-1 and 
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ICAM-1 expression. In vivo, loss of NOR1 function in apoE-deficient mice reduces 
atherosclerosis formation and macrophage recruitment to the arterial wall. These studies 
identify NOR1 as a previously unrecognized key component of a transcriptional cascade 
regulating monocyte adhesion during atherogenesis. 
2.3. Material and Methods 
Immunostaining  
Immunostaining of human atherosclerotic lesions was performed as described 
previously using primary antibodies against NOR1 (1:100 dilution; IMG-71915; Imgenex, 
Inc.) or von Willebrand Factor (vWF) (1:100 dilution; 115-01, SIGNET)94, 95. For 
immunofluorescent co-localization studies, sections were incubated with primary 
antibodies against NOR1 (1:50 dilution; ab56340; Abcam) and vWF (1:100 dilution; 
115-01, SIGNET). Sections were subsequently incubated with Alexa 488-conjugated goat 
anti-mouse antibody (1:1000 dilution, A11001, Invitrogen) and Alexa 594-conjugated goat 
anti-rabbit antibody (1:1000, A11012, Invitrogen), respectively. All studies on human 
tissues were performed with the approval of the University of Kentucky Institutional 
Review Board. 
For immunohistochemical analysis of mouse aortic atherosclerotic lesions, the 
ascending aortae were embedded in OCT (Tissue-Tek; Miles Inc., Elkhart, Illinois, USA) 
and snap-frozen. Transverse cryosections (10 µm) were collected from the aortic arch, 
fixed in cold acetone, and immunostained using macrophage anti-sera (AI-AD 31240, 
Accurate Chemicals) or a VCAM-1 antibody (BD 550547). All experiments on mice were 
approved by the University of Kentucky Institutional Animal Care and Use Committee. 
Cell culture  
Human umbilical vein endothelial cells (HUVEC, Lonza) and human aortic 
endothelial cells (HAEC, Cascade Biologics) were cultured as directed by the 
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manufacturer. Human THP-1 monocytes (ATCC) were maintained in RPMI-1640 medium 
supplemented with 10% FBS. Murine WEHI-274.1 premyelocytic cells (ATCC) were 
cultured in DMEM supplemented with 10% FBS. Confluent endothelial cells were 
stimulated with different cytokines or proinflammatory factors as indicated in the Figure 
Legends. The reagents used in this study included human TNFα (R & D), human IL-1β (R 
& D), human IL-6 (R & D), human IFNγ (R & D), human oxidized low-density-lipoprotein 
(ox-LDL) (INTRACEL), mouse TNFα (R & D), mouse IL-1β (R & D) and LPS (Sigma). 
All experiments were performed with cells between passages 2 to 8, and each experiment 
was repeated at least three times with different preparations of cells. 
Isolation of murine endothelial cells 
Mouse aortic endothelial cells (MAEC) were isolated from aortae of littermate 
NOR1+/+ and NOR-/- mice using an explant technique. Aortic segments were placed on 
Cultrex Basement Membrane Extract gel (R & D Systems) and incubated in low-glucose 
DMEM supplemented with 15 % FBS, 180 µg/ml heparin and 20 µg/ml endothelial cell 
growth supplement. Migrated endothelial cells were passaged using dispase (BD Sciences) 
and cultured for 2 days in media containing D-valine to limit fibroblast contamination. 
Once confluent, MAEC were incubated with TNFα (R & D Systems) as indicated.  
Western blotting 
Western blotting was performed as described using antibodies against NOR1 
(PP-H7833, R & D Systems), human VCAM-1 (BD Pharmingen), human ICAM-1 
(Abcam), mouse VCAM-1 (R & D Systems), mouse ICAM-1 (Abcam), -actin (Sigma), 
and GAPDH (FL 335) (Santa Cruz)94, 95.  
Quantitative real-time RT-PCR 
Total RNA was isolated using TRIzol® (Invitrogen) and reverse transcribed into 
cDNA using SuperScript II (Invitrogen). RNA expression levels of target genes were 
 
25 
quantified using an iQTM SYBR Green Supermix (BioRad) and 5 pmol of the indicated 
primer pairs (Table 2.1). PCR reactions were performed on an iCycler (BioRad) using the 
following PCR cycles: 1 cycle of 95 °C 10 min; 40 cycles of 95 °C 30 sec, 55 °C 30 sec, 
72 °C 30 sec; 1 cycle of a final extension at 72°C for 10 min. Each sample was analyzed in 
triplicate and normalized to expression values of the house-keeping gene TBP or TFIIB. 
Data were calculated using the 2-∆∆CT method137. 
Adenovirus-mediated over-expression in HUVEC 
The adenovirus over-expressing the dominant-negative IκBα mutant 
(IκBα-S32A/S36A) (Ad-CMV-IκB(DN)) was purchased from Vector Biolabs. The 
adenovirus over-expressing human NOR1 (Ad-CMV-NOR1) was generously provided by 
Dr. Peter Tontonoz (University of California, Los Angeles, CA). Sub-confluent HUVEC 
were infected with 25 PFU Ad-CMV-IκB(DN) for 3 hours and 50 PFU Ad-CMV-NOR1 
for 6 hours, respectively. Adenoviruses over-expressing GFP (Ad-CMV-GFP) or an empty 
vector (Ad-CMV-null) were used as controls.  
Plasmids, transient transfections and luciferase assay 
The human NOR1 promoter constructs have previously been described94. The NF-κB 
response elements located at -198bp to -190bp and -595bp to -496bp from the transcription 
initiation site were mutated from GGAGTTTCC to AGAGTTTAA and from 
GGGATTAGCC to ATGATTAGAA using the QuickChange II XL site–directed 
mutagenesis kit (Stratagene). HAEC were transiently transfected with NOR1 promoter 
constructs using promofectin (PromoKine). Following transfection, cells were recovered 
overnight and stimulated with TNFα. The human VCAM-1 promoter construct was 
commercially obtained from Epoch Biolabs Company. The NBRE site located at -2618 bp 
to -2611 bp from the transcription initiation site was mutated from TGACCTTT to 
TCGGAGTT. For overexpression of NOR1, HUVEC were infected with 50 PFU 
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Ad-CMV-Null or Ad-CMV-NOR1 for 6 hours and recovered for 24 hours. Infected cells 
were subsequently transfected with luciferase reporter constructs driven by the VCAM-1 
promoter. Following transfection, cells were recovered in growth media for 2 days. 
Luciferase activities were analyzed using a Dual Luciferase Reporter Assay (Promega). 
Transfection efficiency was normalized to renilla luciferase activities generated by 
cotransfection of 5 ng pRLCMV. 
siRNA experiments 
siRNA experiments were performed using the SMARTpool technology (L003428, 
Dharmacon RNA Technologies), which provides a mix of four different proprietary 
siRNAs specific against human NOR1. HUVEC were seeded at a density of 1.2 × 105 
cells/well in 6-well plates and transiently transfected for 3 h with 30 nM NOR1 siRNA or 
scrambled siRNA using promofectin (PromoKine). Following transfection, cells were 
recovered in complete growth media overnight and subsequently stimulated with TNFα for 
6 h. Fluorescently labeled THP-1 monocytes were added onto the HUVEC monolayers and 
adhesion was quantified after 30 min as indicated in the section "Adhesion assay". 
Chromatin immunoprecipitation (ChIP) assays 
ChIP assays were performed using the EZ-ChIP kit (Millipore) as described94, 95. 
Briefly, HUVEC were stimulated with TNFα and sheared chromatin was 
immunoprecipitated using 5 µg antibodies directed against NF-κB p65 (sc-372x, Santa 
Cruz) or NOR1 (PP-H7833, R & D Systems). Target DNA product was amplified by PCR 
using primer pairs covering the NF-κB binding sites in the NOR1 promoter or the NBRE 
site in the VCAM-1 promoter (Table 2.1). 
Adhesion assay 
HUVEC were infected with 50 PFU Ad-CMV-Null or Ad-CMV-NOR1 for 6 hours 
and recovered for 48 hours. HUVEC treated with TNFα were employed as a positive 
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control. THP-1 monocytes were pre-stained with 5 µM calcein-AM (Sigma-Aldrich) at 
37 °C for 30 minutes. After washing in PBS, fluorescently labeled THP-1 monocytes were 
added onto the HUVEC monolayers at the density of 106 cells/ml. To block VCAM-1 and 
ICAM-1 function, HUVEC monolayers were incubated with blocking antibodies against 
VCAM-1 (25 µg/ml, BBA5, R & D Systems) and ICAM-1 (10 µg/ml, BBA3, R & D 
Systems) for 1 hour prior to the addition of THP-1 monocytes. Non-adherent monocytes 
were washed off after 30 minutes. For mouse monocyte adhesion assays the thoracic aortae 
of littermate NOR1+/+ or NOR1-/- mice were cut into segments, pinned on dental wax, 
and maintained in MAEC growth media supplemented with TNFα (1 ng/ml) or vehicle 
(PBS). After 6 hours, aortae were washed with PBS, and 700 µl of fluorescently labeled 
WEHI-274.1 cells were added at the density of 106 cells/ml. Non-adherent monocytes were 
removed after 30 minutes by washing with PBS. For both experiments, six pictures were 
taken for each condition, and adhesion was quantified by counting fluorescent monocytes 
attached to the endothelium.  
Mice 
Littermate NOR1-/- and NOR1+/+ mice on a mixed C57BL/6J/129Sv background 
were used as previously described94, 95. ApoE-/- mice on a C57BL/6J background (N10) 
were obtained from The Jackson Laboratory (stock #002052) and interbred with NOR1-/- 
mice to obtain NOR1-/-apoE-/- mice. At 8 to 10 weeks of age, littermate female 
NOR1+/+apoE-/-, NOR1+/-apoE-/- and NOR1-/-apoE-/- mice were fed a saturated fat 
enriched diet (TD88137; Harlan Teklad) for 12 weeks for atherosclerosis analysis or for 2 
weeks to analyze NR4A gene expression.  
Atherosclerosis quantification 
Atherosclerosis was quantified as described and reviewed recently in detail138, 139. 
Briefly, after exsanguination aortic tissue was removed from the ascending aorta to the 
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ileal bifurcation and fixed by perfusion with freshly prepared 4 % paraformaldehyde in 
PBS overnight at room temperature. After tissue fixation, the aorta was dissected from the 
adventitia. The intimal surface was exposed by a longitudinal cut through the inner 
curvature of the aortic arch that extended down the whole length of the aortic tree. To 
permit the arch region to be laid out flat, the greater curvature was cut down to the level of 
the subclavian artery. The tissue was laid out, and an image of the aorta was recorded. To 
quantify the extent of intimal surface covered by grossly discernible lesions, image 
analysis was performed with Image-Pro (Media Cybernetics). The extent of atherosclerotic 
lesions was quantified in the arch as defined from the ascending arch to 4 mm distal to the 
left subclavian artery. The data were presented as the percentage of lesion area on the aortic 
arch. 
Quantification of macrophage accumulation  
Macrophage content was quantified in a 2-mm segment as defined from the beginning 
of the ascending aortic arch using a modified technique described by Mach et al140. From 
this segment 180 serial transverse cryosections (10 μm) were collected and placed onto 
twenty slides per mouse. Slides were immunostained for macrophages as described above, 
and the macrophage content was quantified in nine sections 200 µm apart. Macrophage 
accumulation was determined by quantifying the total area positive for macrophage 
staining using computer-assisted image analysis (Image-Pro, Media Cybernetics). Each 
section was quantified by two observers blinded to the experimental design. The data were 
presented as mean area ± SEM positive for macrophage staining for each of the nine 
measurements and their cumulative sum. 
Lipoprotein resolution and quantification 
Lipoproteins were resolved using size exclusions chromatography as described138, 
139. Briefly, serum samples were centrifuged and placed onto a single Sepharose 6 HR 
10/30 column (300 x 10 mm, Pharmacia) with a mobile phase of saline/EDTA run at 0.5 
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ml/min. Fractions (0.5 ml) were collected and cholesterol concentrations were determined 
by placing 100 µl of each fraction into an equivalent volume of cholesterol reagent (Wako 
Chemical Company) that was diluted to half the manufacturer’s instructions.  Assays were 
performed in a 96 well format and absorbance was determined at 600 nm. 
Statistical analysis 
Results were represented as means or medians depending on the distribution of data. 
Unpaired Student’s t-test was utilized to compare the means between two independent 
groups on a single variable. One-way or Two-way ANOVA was used to compare groups. 
The effect of NOR1 on atherosclerosis was compared using the Kruskal-Wallis test 
followed by Dunn Test post-hoc analysis. P values < 0.05 were considered to be 
statistically significant. 
2.4. Results  
NOR1 is expressed in endothelial cells of human coronary atherosclerotic lesions 
To characterize the distribution of NOR1 expression in atherosclerosis, human 
coronary arteries were immunostained for NOR1. NOR1 protein was readily detectable in 
atherosclerotic lesions (Figure 2.1A) but negligible in normal arteries (data not shown). In 
these atherosclerotic sections, high levels of NOR1 immunostaining were observed in the 
endothelial cell layer and in sub-endothelial cells of advanced atherosclerotic lesions. 
Colocalization experiments using confocal microscopy confirmed a typical nuclear 
expression pattern of NOR1 in endothelial cells staining positive for the endothelial cell 
marker vWF (Figure 2.1B).  
NOR1 is induced by inflammatory stimuli in endothelial cells 
In vitro, stimulation of HUVEC with the inflammatory mediators IL-1β, oxidized 
LDL, LPS, or TNFα highly induced NOR1 mRNA expression (Figure 2.2A). In contrast, 
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IL-6 or IFN-γ did not significantly induce NOR1 transcript levels in HUVEC. Considering 
that TNFα elicited a maximal increase in NOR1 expression, subsequent experiments 
focused on the regulation of NOR1 by TNFα. Consistent with previous reports 
characterizing NOR1 as an early response gene93, 129, time-course experiments confirmed a 
maximal induction of NOR1 mRNA after 3 h of TNFα stimulation (Figure 2.2B). This 
increase in NOR1 transcript levels was followed by a maximal induction of NOR1 protein 
expression after 6 h (Figure 2.2C-D). The observed regulation of NOR1 mRNA and protein 
expression by TNFα was dose-dependent revealing a maximal increase of NOR1 
expression with 1 ng/ml TNFα (Figure 2.2E-G, respectively). Finally, TNFα induced a 
similar induction of NOR1 mRNA expression in primary MAEC isolated from NOR1 
wildtype mice (Figure 2.2H). In contrast, the other two members of the NR4A subfamily 
Nur77 and Nurr1 were only modestly induced in NOR1 wildtype cells, and this induction 
was lost in NOR1-/- MAEC. 
NOR1 expression in endothelial cells is mediated through an NF-κB-dependent 
trans-activation of the NOR1 promoter 
NOR1 is primarily regulated through transcriptional mechanisms, and sequence 
analysis of the NOR1 promoter identified several putative NF-κB binding sites. To address 
the functional relevance of these NF-κB sites, endothelial cells were infected with an 
adenoviral construct over-expressing a dominant-negative IκBα mutant. In cells 
over-expressing GFP as control, TNFα treatment resulted in a significant increase of 
NOR1 mRNA expression (Figure 2.3A). In contrast, over-expression of the 
dominant-negative IκBα mutant resulted in an almost complete inhibition of 
TNFα-induced NOR1 mRNA expression. These experiments indicate that TNFα-induced 
NOR1 expression is primarily mediated via NF-κB signaling in endothelial cells. 
To further confirm an NF-κB-dependent transcriptional regulation of NOR1 
expression in endothelial cells, we performed transient transfection assays using a NOR1 
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promoter construct. This 4.0 kb full-length human NOR1 promoter construct includes two 
putative NF-κB binding sites at -595 to -586 and -198 to -190 from the transcription 
initiation site (Figure 2.3B). Stimulation of endothelial cells with TNFα resulted in a 
significant activation of the full-length NOR1 promoter (Figure 2.3C). This induction of 
the NOR1 promoter was maintained upon 5’-deletion to 1.7 kb but completely abolished 
following mutation of the two NF-κB binding sites, confirming that TNFα induces NOR1 
promoter activity via an NF-κB-dependent trans-activation of the promoter. As depicted in 
Figure 2.3D and E, ChIP assays revealed the recruitment of p65 to the NF-κB site in the 
endogenous NOR1 promoter in response to TNFα. Maximal promoter occupancy was 
observed after 3 h, which is consistent with the kinetics of NOR1 mRNA expression in 
response to inflammatory stimuli. In concert, these data demonstrate that TNFα induces 
NOR1 expression through a NF-κB-dependent signaling pathway resulting in the 
subsequent trans-activation of the proximal NOR1 promoter. 
NOR1 positively regulates VCAM-1 and ICAM-1 in endothelial cells 
To explore whether NOR1 is involved in the transcriptional control of endothelial cell 
responses, we next infected HUVEC with an adenovirus overe-xpressing human NOR1 
(Figure 2.4A). As depicted in Figure 2.4B-E, NOR1 over-expression resulted in a 
prominent induction of VCAM-1 and ICAM-1 mRNA and protein expression levels, 
respectively.  
We next employed a murine model to address whether NOR1 is also required for 
VCAM-1 and ICAM-1 expression in endothelial cells. In these experiments, MAEC were 
isolated from littermate NOR1 wildtype and NOR1-deficient mice94, 95. As depicted in 
Figure 2.5A-E, TNFα stimulation profoundly increased VCAM-1 and ICAM-1 mRNA 
and protein expression in NOR1 wildtype MAEC. In contrast, the induction of both 
adhesion molecules was markedly reduced in MAEC isolated from NOR1-deficient mice. 
Similar data were obtained when cells were stimulated with IL-1β or LPS (Figure 2.5F-H).  
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NOR1 trans-activates the VCAM-1 promoter by binding to a canonical NBRE 
consensus site 
We next performed transient transfection assays to investigate the underlying 
mechanism by which NOR1 regulates VCAM-1 expression in endothelial cells. NOR1 
induces transcription by binding to NBRE consensus sites in target gene promoters53. 
Interestingly, sequence analysis of the human VCAM-1 promoter identified a canonical 
NBRE site at -2618 bp from the transcription initiation site (Figure 2.6A). Transient 
transfection of HUVEC with a luciferase reporter construct driven by the human 3.0 kb 
VCAM-1 promoter revealed that over-expression of NOR1 increases VCAM-1 promoter 
activity (Figure 2.6B). However, this transcriptional induction was significantly altered 
upon site-directed mutagenesis of the canonical NBRE motif. ChIP assays subsequently 
confirmed that TNFα induced the recruitment of NOR1 to this NBRE site in the VCAM-1 
promoter (Figure 2.6C). These experiments demonstrate that NOR1 trans-activates the 
VCAM-1 promoter by binding to a NBRE consensus site in the promoter and characterize 
VCAM-1 as NOR1-regulated target gene.  
NOR1 mediates monocyte adhesion by regulating VCAM-1 and ICAM-1 expression  
VCAM-1 and ICAM-1 have both been well characterized to mediate monocyte 
adhesion to the endothelium leading to the infiltration of monocytes into the 
sub-endothelial area and atherosclerosis development141. To investigate whether the 
transcriptional induction of VCAM-1 and ICAM-1 by NOR1 is sufficient to promote 
monocyte adhesion, we analyzed THP-1 monocyte adhesion to HUVEC over-expressing 
NOR1. Stimulation of a HUVEC monolayer with TNFα profoundly increased monocyte 
adhesion, confirming the validity of the assay (Figure 2.7A, upper panel). Compared to 
HUVEC infected with an adenovirus over-expressing an empty vector as control, 
overexpression of NOR1 significantly increased monocyte adhesion in the absence of 
TNFα stimulation (Figure 2.7A and B). Furthermore, monocyte adhesion induced by 
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NOR1 over-expression was almost completely abolished by pre-incubation of HUVEC 
with VCAM-1 and ICAM-1 blocking antibodies (Figure 2.7A and 2.7B). Conversely, acute 
knock-down of NOR1 in HUVEC using siRNA significantly decreased monocyte adhesion 
(Figure 2.7C-D). Collectively, these studies indicate that NOR1 is necessary and sufficient 
for monocyte adhesion and that this activity is mediated primarily by inducing the 
expression of VCAM-1 and ICAM-1. 
To further confirm a causal contribution of NOR1-dependent VCAM-1 and ICAM-1 
expression for monocyte adhesion ex vivo, we performed adhesion assays with aortae 
isolated from NOR1+/+ and NOR1-/- mice. Incubation with TNFα significantly increased 
the adhesion of monocytes to the aortic endothelial cell layer of NOR1 wildtype mice 
(Figures 2.7E-F). However, this inducible adhesion was completely abolished on aortae of 
NOR1-deficient mice. From these findings we infer that NOR1 expression in resident 
endothelial cells is necessary for mediating monocyte adhesion. 
NOR1 deficiency decreases atherosclerosis formation and reduces macrophage 
recruitment in apoE-/- mice  
Considering that monocyte adhesion constitutes a critical initial step for 
atherogenesis141. We next investigated whether NOR1-deficiency decreases 
atherosclerotic lesion development. Consistent with the important function of NOR1 to 
regulate monocyte adhesion ex vivo, homozygous deletion of NOR1 in apoE-/- mice 
resulted in a 52 % reduction of atherosclerosis compared to their wildtype littermates 
(NOR1+/+apoE-/- 14.3 % (n=14), NOR1+/-apoE-/- 14.0 % (n=15), and NOR1-/-apoE-/- 
6.8 % (n=15) median atherosclerotic lesion area of aortic arches; P < 0.05; Figure 2.8A-B). 
NOR1-deficiency revealed no overt effect on cholesterol distribution confirming a direct 
effect of NOR1 on lesion formation (Figure 2.8C). Immunostaining of atherosclerotic 
tissues and quantification of the macrophage content confirmed macrophage-enriched 
lesions in NOR1+/+apoE-/- mice that were considerably less with decreased macrophage 
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content in NOR1-/-apoE-/- mice (Figure 2.8D-F). Finally, while VCAM-1 was readily 
detectable in atherosclerotic lesions from NOR1+/+apoE-/- mice, there was a paucity of 
immunoreactivity for this adhesion molecule noted in the vascular wall of NOR1-/-apoE-/- 
mice (Fig. 2.8G). 
2.5. Discussion 
Monocyte adhesion constitutes a critical event for the initiation of atherosclerosis141; 
however, the molecular mechanisms that orchestrate monocyte-endothelial cell 
interactions are incompletely understood. In the present study, we report a previously 
unrecognized role for the nuclear receptor NOR1 to serve as a transcriptional regulator of 
adhesion molecule expression and monocyte recruitment during atherosclerosis. In 
endothelial cells, NOR1 is rapidly induced by inflammatory stimuli via an 
NF-κB-dependent trans-activation of the NOR1 promoter. Loss and gain-of-function 
studies establish that NOR1 positively regulates VCAM-1 and ICAM-1 expression in 
endothelial cells leading to increased monocyte adhesion. Consistent with the key role of 
NOR1 to promote monocyte adhesion to the endothelium, our studies further demonstrate 
that NOR1 deficiency results in decreased atherosclerosis development and macrophage 
recruitment in apoE-deficient mice.  
Consistent with recent studies, we identified abundant NOR1 expression in 
endothelial cells135 as well as in cells of the sub-endothelial space likely representing 
macrophages and SMC91, 94, 96, 97, 135. However, the transcriptional mechanisms governing 
inducible NOR1 expression in endothelial cells remain elusive. Our data provides evidence 
for an NF-κB-dependent induction of NOR1 transcription during endothelial cell 
inflammation. Inhibition of NF-κB signaling in endothelial cells repressed inducible 
NOR1 expression in response to inflammatory stimulation. Using site-directed 
mutagenesis and ChIP assays, we identified two functional NF-κB sites in the NOR1 
promoter, to which p65 is recruited during inflammatory activation of endothelial cells. 
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Earlier studies have demonstrated that NOR1 expression in endothelial cells is highly 
induced by mitogens through a cAMP response element binding protein 
(CREB)-dependent activation of the proximal region of NOR1 promoter101. Furthermore, 
hypoxia has recently been reported to induce NOR1 in endothelial cells through a 
mechanism involving the hypoxia-inducible factor (HIF) family of transcription factors142. 
These studies, in concert with our data characterizing NOR1 as an NF-κB target gene in 
endothelial cells, point to distinct transcriptional mechanisms regulating the rapid NOR1 
induction in response to various environmental cues. 
Compared with the well-studied early-response genes encoding proteins of the AP-1 
complex, little is known about the physiological function of NOR1 and its regulated target 
genes, yet the high degree of conservation points to an important role in the control of gene 
expression. A previous study has provided initial evidence to support a functional role of 
NOR1 in endothelial cells by demonstrating that NOR1 regulates growth of this cell type101. 
The data presented here extends these findings and points to an unsuspected function of 
NOR1 to serve as a positive regulator of monocyte adhesion. In experiments using 
adenoviral-mediated over-expression, NOR1 induced VCAM-1 and ICAM-1 expression 
resulting in increased monocyte adhesion. The observation that this inducible adhesion 
was abolished when VCAM-1 and ICAM-1 function were blocked, suggests that the 
induction of both adhesion molecules by NOR1 constitutes a primary mechanism by which 
NOR1 induces monocyte adhesion. Conversely, the inducible expression of both adhesion 
molecules in response to inflammatory activation was attenuated in NOR1-deficient 
endothelial cells. Furthermore, consistent with these findings, TNFα-induced monocyte 
adhesion to HUVEC transfected with NOR1 siRNA or to the endothelium of 
NOR-deficient mice was altered ex vivo, suggesting that vascular NOR1 expression is not 
only sufficient but also required for monocyte adhesion.  
An intriguing question that arises from the observation that NOR1 induces the 
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expression of VCAM-1 and ICAM-1 relates to the mechanisms by which NOR1 positively 
regulates these genes. Initial sequence analysis identified putative NBRE consensus sites 
in both the VCAM-1 and ICAM-1 promoters. Exemplified by the VCAM-1 promoter, our 
studies demonstrate that the molecular mechanisms underlying this novel function of 
NOR1 involve at least in part a direct trans-activation of the VCAM-1 promoter by NOR1. 
In response to inflammatory activation NOR1 is recruited to a canonical NBRE site in the 
VCAM-1 promoter. Moreover, the observation that NOR1-dependent VCAM-1 promoter 
trans-activation was attenuated upon mutation of this NBRE site confirms the functionality 
of this NBRE motif. However, the residual induction of the VCAM-1 promoter bearing a 
mutation of this NBRE site suggests that additional transcriptional mechanisms may 
regulate NOR1 expression. NOR1 has recently been shown to trans-activate the inducible 
IκB kinase (IKKi/IKKepsilon) promoter, which phosphorylates IκBα and induces NF-κB 
activation143. Therefore, in addition to a direct trans-activation, NOR1 may function as a 
positive upstream regulator of NF-κB signaling and indirectly activate the VCAM-1 and 
ICAM-1 promoters. Alternatively, NOR1 deficiency may affect other transcriptional 
networks acting on these promoters, including for example the AP-1 complex. We have 
recently demonstrated that the combined deficiency of NOR1 and its sibling Nur77 
decreases the expression of AP-1 transcription factors121, which may regulate adhesion 
molecule expression144. Clearly, the findings presented here provide justification for 
further investigating the transcriptional mechanisms by which NOR1 regulates endothelial 
cell gene expression and promotes monocyte adhesion.  
The protein products of the VCAM-1 and ICAM-1 genes are well established to 
participate in atherogenesis by promoting macrophage accumulation in the arterial 
intima141. Consistent with this evidence and with the observed regulation of endothelial 
cell adhesion molecule expression by NOR1, we provide the first evidence that NOR1 
deficiency decreases atherosclerosis in apoE-deficient mice. Considering that all three 
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members of the NR4A receptor subfamily bind to an NBRE site, functional redundancy in 
certain cell types between Nur77 and NOR1 has been suggested114. However, 
NOR1-deficiency did not result in a compensatory upregulation of the siblings Nur77 and 
Nurr1 in endothelial cells (Figure 2.2H) or in the aortae of NOR1-/-apoE-/- mice (Figure 
2.9). Therefore, the previously reported phenotypes in NOR1-deficient mice95, 133, 134. In 
concert with the decreased atherosclerosis in NOR1-/-apoE-/- mice presented in this study, 
point to a function of NOR1 that is distinct and not compensated by Nur77 or Nurr1. As 
evidenced by the decreased accumulation of macrophages in the vascular wall of 
NOR1-/-apoE-/- mice, monocyte recruitment represents at least one plausible mechanism 
by which NOR1 acts atherogenic. However, it is possible if not likely that there are 
additional mechanisms by which NOR1 promotes atherosclerosis development. NOR1 
induces neointimal proliferation of SMC 95 and inflammatory gene expression in 
macrophages143, which both could affect lesion development. Therefore, characterization 
of the cell-specific role of NOR1 in atherosclerosis will be necessary and will have to rely 
on tissue-specific gene targeting strategies. In conclusion, data presented here characterize 
the orphan nuclear receptor NOR1 as a novel positive regulator of monocyte adhesion by 
inducing VCAM-1 and ICAM-1 transcription. Continued investigation of the 
transcriptional networks regulated by NOR1 will provide new insights into how this 
orphan nuclear receptor participates in the development of vascular diseases.
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Table 2.1. Oligonucleotides used in this study 
Name  Use  Sequence  
human NOR1 
Real-time 
RT-PCR 
F : 5’-GGGCTTTTTCAAGAGAACAGTG-3’  
R: 5’-ATCTCTGGGTGTTGAGTCTGTT-3’ 
human VCAM-1 
Real-time 
RT-PCR 
F: 5’-TGAGGGGACCAATTCCAC-3’ 
R: 5’-ATTCACGAGGCCACCACT-3’ 
human ICAM-1 
Real-time 
RT-PCR 
F: 5’-ACCGTGAATGTGCTCTCC-3’ 
R: 5’-GGCTTGTGTGTTCGGTTT-3’ 
murine VCAM-1 
Real-time 
RT-PCR 
F: 5’-TCAAAGAAAGGGAGACTG-3’ 
R: 5’-GCTGGAGAACTTCATTATC-3’ 
murine ICAM-1 
Real-time 
RT-PCR 
F: 5’-AGATCACATTCACGGTGCTG-3’ 
R: 5’-CTTCAGAGGCAGGAAACAGG-3’ 
human TBP  
Real-time 
RT-PCR  
F: 5’-GGAGAGTTCTGGGATTGTACCGC-3’ 
R: 5’-ATATTCGGCGTTTCGGGCAC-3’ 
murine TFIIB 
Real-time 
RT-PCR 
F: 5’-CTCTCCCAAGAGTCACATGTCC-3’ 
R: 5’-CAATAACTCGGTCCCCTACAAC -3’ 
murine NOR1 
Real-time 
RT-PCR 
F: 5’-GGCCGCAGCTGCACTCAGTC -3’ 
R: 5’-GCGGAGGGAAGGTCAGCGTG -3’ 
murine Nur77 
Real-time 
RT-PCR 
F: 5’-TTGATGTTCCCGCCTTTG-3’ 
R: 5’-GGTAGCCATGTGCTCCTTC-3’ 
murine Nurr1 
Real-time 
RT-PCR 
F: 5’-TCACCTCCGGTGAGTCTGATC-3’ 
R: 5’-TGCTGGATATGTTGGGTATCATCT-3’ 
hNOR1-NFKB  ChIP PCR 
F: 5’-CCATCTGCATCCCTGTGT-3’ 
R: 5’-GCTGCACTTTCCTCTTGC-3’  
hVCAM-1-NOR1 ChIP PCR 
F: 5’-CTGTACTCAAACATTGGAAACATT -3’ 
R: 5’-CCTTAGAGATGAGAGAAGCAAGA-3’  
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Figure 2.1. NOR1 is present in endothelial cells of human coronary atherosclerotic 
lesions 
Sections of atherosclerotic human coronary arteries were immunostained for NOR1 and 
von Willebrand Factor (vWF) to identify endothelial cells. Species-matched normal IgG 
served as negative control. Images were acquired using (A) light microscopy and (B) 
confocal microscopy. In (B) stainings for NOR1, vWF and DAPI were merged into one 
image as indicated. Objective magnifications are indicated.  
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Figure 2.2. NOR1 is induced by inflammatory stimuli in endothelial cells 
(A) HUVEC were stimulated as indicated for 2 hours and NOR1 mRNA expression was 
analyzed. (B-D) HUVEC were stimulated with TNFα (1 ng/ml) and NOR1 mRNA (B) and 
protein expression (C) were analyzed at the indicated time points. (D) Densitometric 
analysis of NOR1 protein expression in (C). (E-G) HUVEC were stimulated with vehicle 
(PBS) or the indicated doses of TNFα. NOR1 mRNA (E) and protein (F) expression were 
analyzed after 2 hours or 6 hours, respectively. (G) Densitometric analysis of NOR1 
protein expression in (F). NOR1 mRNA expression levels were normalized to hTBP and 
presented as mean ± SEM fold increase over vehicle-treated cells (*P < 0.05 vs. vehicle). 
Densitometric analysis was performed on three independent experiments. Cohybridization 
for GAPDH was performed to assess equal loading. (H) NOR1+/+ and NOR1-/- MAEC 
were incubated with TNFα (5 ng/ml) and mRNA expression of NOR1, Nur77 and Nurr1 
was analyzed by real-time RT-PCR. Experiments were repeated at least three times in 
duplicate with different cell preparations. Results are presented as mean ± SEM fold 
increase over vehicle-treated wildtype cells (*P < 0.05 vs. vehicle).  
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Figure 2.3. NOR1 expression in endothelial cells is mediated through 
NF-κB-dependent signaling pathways 
(A) HUVEC were infected with 25 PFU Ad-CMV-IκB(DN) or Ad-CMV-GFP and 
stimulated with vehicle (PBS) or TNFα (1 ng/ml) for 2 hours. NOR1 mRNA expression 
was analyzed and normalized to hTBP. Data are presented as mean ± SEM fold increase 
over Ad-CMV-GFP-infected cells treated with vehicle (*p < 0.05 vs. vehicle; #p < 0.05 vs. 
Ad-CMV-GFP). (B) Schematic structure of the human 4.0 kb and 1.7 kb NOR1 promoter 
constructs. (C) HAEC were transfected with a luciferase reporter construct driven by the 
indicated NOR1 promoter, stimulated with vehicle (PBS) or TNFα (10 ng/ml), and 
analyzed for luciferase activities. Data are presented as mean ± SEM from three 
independently performed experiments (*p < 0.05 vs. vehicle; #p < 0.05 vs. 
pNOR1-1.7kb-WT). (D-E) HUVEC were stimulated with TNFα (1 ng/ml) and harvested 
at the indicated time point for ChIP assays. Chromatin complexes were 
immunoprecipitated with an antibody against NF-κB p65 or species-matched IgG. PCR 
products were amplified using primers covering the -595 bp to -586 bp NF-κB binding site. 
(D) The autoradiograms are representative of three independently performed experiments. 
(E) Densitometric analysis of NF-κB p65 binding normalized to input from three 
independently performed experiments. 
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Figure 2.4. NOR1 induces VCAM-1 and ICAM-1 expression in endothelial cells 
(A-E) HUVEC were infected with 50 PFU Ad-CMV- NOR1 or Ad-CMV-GFP. (A) 
Western Blotting confirmed NOR1 over-expression after transduction. (B) VCAM-1 and 
ICAM-1 mRNA expression was determined by real-time RT-PCR. Experiments were 
performed at least three times in triplicate. Data were calculated by normalizing NOR1 
values to hTBP values and presented as mean ± SEM fold induction over Ad-CMV-GFP 
infected cells (*p < 0.05 vs. Ad-CMV-GFP). (C-E) VCAM-1 and ICAM-1 protein 
expression was analyzed by Western blotting. Cohybridization for actin was performed to 
assess equal loading. (C)  Representative autoradiograms and densitometric analysis (D 
and E) of three independently performed experiments. 
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Figure 2.5. NOR1 is required for VCAM-1 and ICAM-1 expression in endothelial 
cells 
(A-E) NOR1+/+ and NOR1-/- MAEC were stimulated with vehicle or TNFα (1 ng/ml) for 
6 hours. VCAM-1 and ICAM-1 mRNA (A and B) and protein (C-E) expression were 
analyzed by real-time RT-PCR and Western blotting, respectively. (C) The autoradiograms 
are representative of three independent experiments. (D and E) Densitometric analysis of 
VCAM-1 and ICAM-1 protein expression after Western blotting. All experiments were 
repeated at least three times in duplicate with different cell preparations. Results are 
presented as mean ± SEM fold increase over vehicle-treated wildtype cells (*P < 0.05 vs. 
vehicle, # P < 0.05 vs. NOR1+/+ cells). (F-H) NOR1+/+ and NOR1-/- MAEC were 
stimulated with vehicle, IL-1β (1 ng/ml), or LPS (50 ng/ml) for 6 hours. VCAM-1 and 
ICAM-1 protein expression were analyzed by Western blotting. Cohybridization for actin 
was performed to assess equal loading. (F) Autoradiograms are representative of three 
different experiments. (G and H) Densitometric quantification of VCAM-1 and ICAM-1 
protein expression from three experiments with different cell preparations. Results are 
presented as mean ± SEM fold increase over vehicle-treated wildtype cells (*P < 0.05 vs. 
vehicle, # P < 0.05 vs. NOR1+/+ cells).  
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Figure 2.6. NOR1 trans-activates the VCAM-1 promoter by binding to an NBRE 
consensus site 
(A) Schematic structure of the human 3.0 kb VCAM-1 promoter and the NBRE consensus 
site at -2618 bp. (B) HUVEC were infected with 50 PFU Ad-CMV-Null or 
Ad-CMV-NOR1 for 6 hours and recovered for 24 hours. Infected cells were transiently 
transfected with luciferase reporter constructs driven by the VCAM-1 wildtype promoter 
or the similar promoter bearing a mutation in the NBRE site. Luciferase activities were 
analyzed after 48 hours. Data are presented as mean ± SEM fold induction from three 
independently performed experiments (*p < 0.05 vs. empty vector; #p < 0.05 vs. 
pVCAM-1-WT). (C) HUVEC were stimulated with vehicle (PBS) or TNFα (1 ng/ml) for 
ChIP assays. PCR for an unrelated promoter fragment in the β-actin promoter served as 
control for specificity. The autoradiograms are representative of three independently 
performed experiments. 
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Figure 2.7. NOR1 mediates monocyte adhesion by regulating VCAM-1 and ICAM-1 
expression 
(A) Upper panel: HUVEC were infected with 50 PFU Ad-CMV-NOR1 or Ad-CMV-Null, 
and fluorescently labeled THP-1 monocytes were added onto HUVEC monolayers. 
TNFα-treated (1 ng/ml) HUVEC were employed as a positive control. Lower panel: 
Ad-CMV-NOR1-infected cells were pre-incubated with VCAM-1 and ICAM-1 blocking 
antibodies (B/N) or control IgG. After 1 hour, fluorescently labeled THP-1 monocytes were 
added onto HUVEC monolayers. (B) Quantification is presented as mean ± SEM from 
three independently performed experiments in duplicate (*p < 0.05 vs. vehicle or 
Ad-CMV-Null, # p < 0.05 vs. TNFα, § p < 0.05 vs. IgG). (C and D) siRNA-mediated 
knock-down of NOR1 expression decreased monocyte adhesion. (C) HUVEC were 
transfected with scrambled or NOR1 siRNA, stimulated with TNFα (1 ng/ml), and 
analyzed for THP-1 monocyte adhesion. Representative images showing monocyte 
adhesion. (D) Quantification is presented as mean ± SEM from three independently 
performed experiments in duplicates (*P < 0.05 vs. vehicle, # P < 0.05 vs. scrambled 
siRNA). (E and F) Aortae were isolated from NOR1+/+ and NOR1-/- mice and 
TNFα-induced monocyte adhesion was analyzed. (E) Representative sections 
demonstrating adhesion of monocytes. (F) Quantification of adhesion from three 
independent experiments performed in duplicate using different aortic preparations. Data 
are expressed as mean ± SEM (*P < 0.05 vs. vehicle, # P < 0.05 vs. NOR1+/+ cells). 
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Figure 2.8. NOR1 deficiency decreases atherosclerosis in apoE-/- mice 
(A) Atherosclerotic lesion size was measured on aortic arches from female 
NOR1+/+apoE-/- (n=14), NOR1+/-apoE-/- (n=15) and NOR1-/-apoE-/- (n=15) mice. 
Circles and triangles represent individual mice; diamonds represent medians (P < 0.05 
between group, *P < 0.05 vs. NOR1+/+apoE-/-). (B) Representative aortic arches from 
each genotype. (C) Lipoprotein cholesterol distributions. Values represent the mean 
cholesterol content of each fraction (± SEM). (D-G) Serial sections from a 2-mm segment 
beginning at the lesser curvature of the aortic arch were collected from NOR1+/+apoE-/- 
and NOR1-/-apoE-/- mice. Sections of atherosclerotic lesions were immunostained using 
antisera against macrophages or VCAM-1. (D) Representative sections for macrophage 
staining (top) or IgG (bottom) (objective magnification ×20). (E) Macrophage content was 
quantified in nine sections 200 µm apart using computer-assisted image analysis. Data are 
presented as mean area in mm2 ± SEM. Statistical analysis was performed using factorial 
ANOVA test. No significant difference between single segments of the arch in 
NOR1+/+apoE-/- and NOR1-/-apoE-/- mice was detected. (F) Macrophage accumulation 
was quantified in the entire aortic arch from NOR1+/+apoE-/- and NOR1-/-apoE-/- mice 
(*P < 0.05 vs. NOR1+/+apoE-/-). (G) Representative sections for VCAM-1 staining 
(objective magnification ×20 and x100).  
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Figure 2.9. The expression of NR4A nuclear receptors in mouse aortic arteries in 
response to high-fat diet feeding 
NOR1+/+apoE-/- (n=5) and NOR1-/-apoE-/- (n=5) mice were fed a diet enriched in 
saturated fat for 2 weeks. Aortae were collected and mRNA expression of NOR1, Nur77 
and Nurr1 was analyzed by real-time RT-PCR. Results are presented as mean ± SEM fold 
increase over NOR1+/+apoE-/- mice. Note, no NOR1 transcript was detected in 
NOR1-/-apoE-/- mice (N.D., not detectable). 
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Chapter three: Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by 
histone deacetylase inhibition 
This part is in manuscript preparation for submission. 
3.1. Synopsis 
Many nuclear receptors function as key transcriptional regulators of gene expression 
in cardiovascular diseases. While most nuclear receptors are ligand-dependent 
transcription factors, members of the NR4A subfamily function as immediate/early 
response genes whose transcriptional activity is dependent on their expression level or 
their posttranslational modification. In our previous studies, we established that the 
neuron-derived orphan receptor 1 (NOR1) of the NR4A subfamily serves a mitogenic role 
and promotes neointima formation. In smooth muscle cells, NOR1 is induced through 
phosphorylation of the cAMP response element binding protein (CREB) and subsequent 
binding of phosphorylated CREB to the NOR1 promoter. In the current study, we extend 
these observations and demonstrate that NOR1 expression is enhanced by inhibition of 
histone deacetylation. Pre-treatment of smooth muscle cells with the histone deacetylase 
(HDAC) inhibitor scriptaid potentiated and sustained PDGF-induced NOR1 mRNA and 
protein expression. Conversely, specific small interfering RNA-mediated knockdown of 
HDAC3 augmented PDGF-induced NOR1 mRNA expression. Scriptaid increased NOR1 
promoter activity in reporter assays without affecting NOR1 transcript stability. This 
increased NOR1 transcription was associated with enhanced CREB phosphorylation by 
HDAC inhibition. Chromatin immunoprecipitation assays further confirmed that HDAC 
inhibition increased histone acetylation at CREB binding sites in the NOR1 promoter 
region and results in increased binding of phosphorylated CREB to its consensus sites. 
Finally, we demonstrate that HDAC inhibition also increases NOR1 protein half-life. 
Collectively, these data suggest that HDAC inhibition increases NOR1 expression at 
multiple levels, including gene transcription and protein stability. These findings may have 
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important implications for understanding the epigenetic mechanisms orchestrating the 
expression of this mitogenic transcription factor. 
3.2. Introduction 
Epigenetic traits are considered as chromosome modifications that regulate gene 
transcription without altering DNA sequences30, 42. These modifications can be translated 
into signals dictating gene activation/repression30, 42. One factor involved in epigenetic 
regulation is the chemical modification of histone tails, including acetylation, methylation, 
phosphorylation, ubiquitination, and sumoylation, all of which regulate the degree of gene 
expression33, 34. The acetylation status of chromatin is determined by the dynamic 
opposing functions of histone acetyl-transferases (HAT) and histone deacetylases (HDAC). 
HAT add acetyl-groups to histones and create a hyperacetylated chromatin environment 
which is associated with gene activation33, 34. HDAC remove acetyl-groups resulting in a 
condensed chromatin structure which is associated with gene repression33, 34. Additionally, 
HAT and HDAC also add/remove acetyl-groups to/from the lysine residues of non-histone 
proteins38. To date, eighteen human HDAC have been identified and they are grouped into 
four classes based on their sequence homology to yeast HDAC: Class I (HDAC 1, 2, 3 and 
8), Class II (HDAC 4, 5, 6, 7, 9 and 10), Class III (SIRT 1-7), and Class IV (HDAC11)38, 145.  
HDAC inhibitors (HDACi) are chemical HDAC modulators which interact with HDAC 
and inhibit their activity with distinct potency and specificity38, 145-147. Initially studied as 
anti-cancer agents, HDACi have been shown to promote cell differentiation, growth arrest, 
apoptosis and senescence in cancer cells38, 145, 148. Further studies revealed that HDACi 
have pleiotropic effects on other cell types. HDACi have been shown to inhibit vascular 
smooth muscle cell (SMC) proliferation and prevent mechanically induced SMC 
migration149, 150. Additional evidence suggests an antithrombotic role of HDACi in 
suppressing tissue factor expression in endothelial cells and monocytes151. HDACi have 
also been shown to block inflammatory cytokine production in macrophages and dendritic 
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cells152, 153. Additionally, treatment with HDACi enhanced the pool of beta cells and 
protected beta cells from cytokine induced cell death154, 155.  
Nuclear receptors (NR) function as key transcriptional regulators of gene expression. 
They share structurally conserved domains including N-terminal trans-activation domain, 
central DNA binding domain and C-terminal ligand binding domain. In addition to 
ligand-activated NR such as peroxisome proliferator-activated receptors (PPAR) and liver 
X receptors (LXR), a group of orphan NR has been demonstrated to function as 
ligand-independent NR. The primary mechanism by which NR regulate gene expression 
is through recognizing and binding to their consensus response elements on target 
promoters. The transcription complex initiated by NR binding further requires 
HAT/HDAC activities to activate/silence gene transcription. cAMP response element 
binding protein (CREB)-binding protein (CBP) and its homolog p300 are well 
characterized transcription co-activators and their HAT activities are essential for 
NR-dependent trans-activation156, 157. Nuclear receptor co-repressors (NCoR) have been 
shown to interact with HDAC3 to silence NR target gene expression in the absence of 
ligand binding158. In addition, the expression level of NR is also controlled by epigenetic 
regulation. For instance, DNA hypermethylation within the promoter region plays a 
fundamental role in silencing the expression of estrogen receptor alpha (ERα) and 
androgen receptor (AR)159. Furthermore, the acetylation status of NR is also regulated by 
HAT and HDAC, which influence NR ligand sensitivity and transcriptional activity159. 
The neuron-derived orphan receptor 1 (NOR1) belongs to the ligand-independent 
NR4A subfamily, a group of nuclear receptors which have been demonstrated to function 
as immediate/early response genes. Transcriptional activity of the NR4A NR is dependent 
on their expression level and post-translational modifications. Members of the NR4A 
subfamily, including Nur77 (NR4A1), Nurr1 (NR4A2) and NOR1 (NR4A3), can be 
induced by a wide range of physiological/pathological signals in different tissues52, 160. 
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This induction often involves de novo RNA synthesis through transcriptional activation of 
the NR4A promoters. In addition, NR4A orphan receptors are also subjected to 
phosphorylation, sumoylation and acetylation modifications, which could affect their 
transcriptional activity63, 68, 161. We have previously demonstrated that NOR1 plays a 
mitogenic role in vascular SMC, and NOR1 deficiency suppresses SMC proliferation and 
decreases neointima formation61, 94, 95. A key biological event regulating mitogen-induced 
NOR1 expression is CREB phosphorylation and the recruitment of phospho-CREB to the 
consensus cAMP response elements (CRE) in the NOR1 promoter94, 106, 162. However, it 
remains unknown whether phospho-CREB modifies the chromatin architecture at the 
NOR1 promoter. In this study, we demonstrate that HDAC inhibition and platelet-derived 
growth factor (PDGF) synergistically up-regulate NOR1 expression in SMC through 
modifying the histone acetylation status of chromatin in the NOR1 promoter. 
3.3. Materials and Methods 
Cell culture  
Rat aortic smooth muscle cells (RASMC) were purchased from Lonza and 
maintained in DMEM supplemented with 10 % FBS. RASMC were starved in 0.01 % 
FBS DMEM for 48 hours when they were 70 % confluent. Quiescent cells were 
pretreated with Scriptaid (Sigma) (2 µg/ml) for 30 min and stimulated with rat PDGF-BB 
(R & D Systems) (25 ng/ml) for indicated time points. For mRNA stability assays, 
actinomycin D (Sigma) (10 µg/ml) was added to cell cultures to inhibit mRNA 
transcription. For protein stability assays, cycloheximide (Sigma) (10 µg/ml) was added 
to cell cultures to inhibit protein synthesis. 
Quantitative real-time RT-PCR  
Total RNA was isolated using TRIzol® (Invitrogen) and reverse transcribed into 
cDNA using SuperScript II (Invitrogen). RNA expression levels of target genes were 
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quantified using an iQTM SYBR Green Supermix (BioRad). Primers used in this study are 
listed: NOR1, forward:  5’-CAGCAGCTGCGAACTCAA-3’; reverse: 
5’-CGGTGTAGAAGGCGGAGA-3’; HDAC1, forward: 
5’-CCATCAAAGGACATGCCAAGT-3’; reverse: 
5’-CGAGCGACATTACGGATGGT-3’; HDAC2, forward: 
5’-CGGCAAGAAGAAAGTGTGCTACT-3’; reverse: 
5’-ATGAGTCATCCGGATCCTATGG-3’; HDAC3, forward: 
5’-GCACCCGCATCGAGAATC-3’; reverse: 5’-TGGACACTGGGTGCATGGT-3’; 
RPL13A, forward: 5’GTACGCTGTGAGGGCATCAA-3’; reverse: 
5’-CTCGAGACGGGTTGGTGTTC-3’. PCR reactions were performed on an iCycler 
(BioRad) using the following PCR cycles: 1 cycle of 95 °C 10 min; 40 cycles of 95 °C 30 
sec, 55 °C 30 sec, 72 °C 30 sec; 1 cycle of a final extension at 72°C for 10 min. Each 
sample was analyzed in triplicate and normalized to expression values of the 
house-keeping gene RPL13A. Data were calculated using the 2-∆∆CT method137. 
Western blotting 
Western blotting was performed as previously described using antibodies against 
NOR1 (R & D Systems), phospho-Ser133 CREB (Cell Signaling), CREB (Cell Signaling) 
and GAPDH (FL 335) (Santa Cruz)94, 163. 
Plasmids, transient transfections and luciferase Assay 
The NOR1 promoter constructs have previously been described94. RASMC were 
transiently transfected with 2 µg NOR1 promoter constructs for 6 hours using 
lipofectamine (Invitrogen) in OPTI-MEM. Following transfection, cells were starved in 
0.4% FBS DMEM and stimulated with scriptaid (2 µg/ml) for overnight. Luciferase 
activities were analyzed using a Dual Luciferase Reporter Assay (Promega). Transfection 
efficiency was normalized to renilla luciferase activities generated by cotransfection of 
pRL-null-renilla. 
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Chromatin immunoprecipitation (ChIP) assays 
ChIP assays were performed using the MAGnifyTM Chromatin Immunoprecipitation 
System (Invitrogen) according to the manufacturer's instructions. Briefly, quiescent 
RASMC were pre-treated with scriptaid (2 µg/ml) for 30 min and stimulated with PDGF 
(25 ng/ml) for indicated time points. Sheared chromatin was immunoprecipitated using 
antibodies against phospho-Ser133 CREB (Cell Signaling), AcH3K9 (Cell Signaling). 
Target DNA product was amplified by PCR using primer pairs covering the three CRE 
consensus sequences between -79 and -46 in the NOR1 promoter: forward, 
5’-ACACACACCCTCGCACAC-3’; reverse, 5’-TCGGCACGTCATTTATGC-3’. 
siRNA-mediated HDAC1-3 knockdown  
siRNA experiments were performed using the SMARTpool technology (Dharmacon 
RNA Technologies), which provides a mix of four different proprietary siRNAs specific 
for the target gene. RASMC were transfected with HDAC1, HDAC2, HDAC3 or 
scrambled siRNA (50 nM) using LipofectamineTM RNAiMAX (Invitrogen) for 6 hours. 
Following transfection, cells were recovered in growth media overnight and starved in 
0.01 % FBS DMEM for 48 hours, which was followed by stimulation with PDGF (25 
ng/ml) for 6 hours.  
Statistical analysis 
Results were represented as means ± SEM. Unpaired Student’s t-test was utilized to 
compare the means between two independent groups on a single variable. One-way or 
Two-way ANOVA was used to compare groups. P values < 0.05 were considered to be 
statistically significant. 
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3.4. Results 
NOR1 expression is enhanced by HDAC inhibitor Scriptaid in vascular SMC 
To investigate the epigenetic regulation of NOR1 expression by histone acetylation, 
we employed the HDACi Scriptaid. Scriptaid is a hydroxamic acid-containing HDACi 
and has been reported to increase histone acetylation with low cytotoxicity164. 
Pre-treatment with Scriptaid (2 µg/ml) potentiated NOR1 mRNA and protein expression 
in response to PDGF (25 ng/ml) in vascular SMC. This effect was more apparent at the 
later time point after PDGF stimulation (Figure 3.1A and B). Scriptaid alone also induced 
NOR1 mRNA expression in quiescent vascular SMC, while control vehicle (DMSO) did 
not have any effect, which indicates that HDAC activity is required to suppress NOR1 
expression in the quiescent SMC (Figure 3.1C). However, Scriptaid treatment without 
mitogenic stimulation only induced modest NOR1 expression compared to co-stimulation 
with PDGF (Figure 3.1A and C). Collectively, these experiments suggest that cooperation 
between mitogenic stimulation and hyperacetylation is important for maximal and 
sustained NOR1 expression in vascular SMC.  
siRNA-mediated knockdown of HDAC3 expression increases PDGF-induced NOR1 
mRNA expression 
Scriptaid functions as a pan-HDAC inhibitor, primarily targeting to Class I and Class 
II HDACs. In order to investigate which HDAC regulates NOR1 mRNA expression, 
vascular SMC were transiently transfected with siRNA against HDAC1, HDAC2 and 
HDAC3 followed by PDGF stimulation. siRNA mediated knockdown of HDAC1-3 was 
confirmed by quantitative RT-PCR (Figure 3.2A). Acute knockdown of HDAC3 
significantly enhanced NOR1 mRNA expression at the basal level and after PDGF 
stimulation, while HDAC1 or HDAC2 knockdown had no effect on NOR1 mRNA 
expression (Figure 3.2B). Therefore, these experiments indicate that the HDACi Scriptaid 
increases NOR1 mRNA expression through the regulation of HDAC3. 
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Scriptaid increases NOR1 promoter activity without affecting NOR1 transcript 
stability 
mRNA accumulation is generally due to transcription activation, transcript 
stabilization or both. To understand the mechanism by which NOR1 mRNA is increased 
by HDAC inhibition, NOR1 promoter activity was first analyzed. We performed transient 
transfection assays with reporter constructs driven by a 1.7kb NOR1 promoter and 
demonstrated that Scriptaid increased NOR1 promoter activity in vascular SMC (Figure 
3.3A). In order to analyze the effect of Scriptaid on NOR1 mRNA stability, vascular 
SMC were pre-treated with Scriptaid or DMSO as control and followed by PDGF 
stimulation for 2 hours to induce NOR1 mRNA accumulation. Actinomycin D (10 µg/ml) 
was then added to cell cultures to inhibit mRNA transcription. As depicted in Figure 3.3B, 
Scriptaid treatment did not have any effect on NOR1 mRNA stability. In summary, these 
two experiments demonstrate that Scriptaid increases NOR1 mRNA expression by 
activating NOR1 transcription. 
Scriptaid enhances CREB phosphorylation and the recruitment of phospho-CREB 
to its binding sites in the NOR1 promoter 
We next continued to investigate the mechanisms by which Scriptaid activates 
NOR1 transcription. We have previously demonstrated that CREB phosphorylation and 
the recruitment of phospho-CREB to the NOR1 promoter are required for NOR1 
transcription activation in response to PDGF94. Therefore, CREB phosphorylation was 
analyzed. Interestingly, Scriptaid alone rapidly induced CREB phosphorylation within 30 
min pre-treatment, although this effect was modest compared to PDGF stimulation 
(Figure 3.4A). As expected, PDGF-induced CREB phosphorylation was strongly 
enhanced by Scriptaid at each time point of this experiment (Figure 3.4A), which may 
account for the augmented NOR1 mRNA expression with scriptaid pre-treatment (Figure 
3.1A). 
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HDAC inhibition has been demonstrated to increase histone acetylation which is 
associated with chromatin decondensation and gene activation34, 38. To test this possibility, 
histone acetylation in the NOR1 promoter region that contains the CRE sites was 
analyzed by ChIP assays. Increased H3-lysine9 acetylation (AcH3K9) has been shown to 
correlate with gene activation33. Analyses with antibodies against AcH3K9 demonstrated 
that Scriptaid alone increased histone acetylation at the CRE binding sites in the NOR1 
promoter (Figure 3.4B). This increased histone acetylation caused a corresponding 
increase in the binding of phospho-CREB to the same region in the NOR1 promoter 
(Figure 3.4C). As expected, Scriptaid pre-treatment further enhanced PDGF-induced 
histone H3 acetylation and phospho-CREB recruitment at the CRE sites in the NOR1 
promoter (Figure 3.4B and C). Collectively, these findings suggest that HDAC inhibition 
by itself can increase phospho-CREB binding to the NOR1 promoter; however, upstream 
signaling induced by mitogenic stimulation is required for further chromatin 
decondensation and phospho-CREB enrichment, which ensures maximal NOR1 
transcription.  
HDAC inhibitor Scriptaid increases NOR1 protein stability 
Post-translational modification of NR by acetylation and deacetylation has been 
demonstrated to regulate NR stability, ligand binding sensitivity and transcription 
activity159, 161, 165, 166. Here we demonstrate that pre-treatment with HDACi Scriptaid 
increases NOR1 protein half-life in response to PDGF stimulation (Figure 3.5A and B). 
Collectively, HDACi Scriptaid enhances NOR1 expression at both the transcriptional and 
post-translational levels. 
3.5. Discussion 
The complex initiated by the interaction of NR with co-activators/co-repressors also 
involves histone modifier proteins facilitating gene activation and silencing167. In 
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addition to regulating chromatin dynamics, NR themselves are also subjected to the 
control by histone modifier proteins159. The transcriptional activity of NOR1 is primarily 
determined at the expression level and by post-translational modifications160. NOR1 has 
previously been demonstrated to mediate mitogenic signaling in vascular SMC and its 
deficiency suppresses SMC proliferation93-95. In the present study, we demonstrate that 
NOR1 is induced, although modestly, by HDACi Scriptaid in vascular SMC. HDAC 
inhibition and mitogenic stimuli have a synergistic effect on activating NOR1 
transcription by increasing CREB phosphorylation and the recruitment of phospho-CREB 
to the NOR1 promoter. Finally, we demonstrate that NOR1 protein stability is increased 
by HDAC inhibition. Therefore, our findings provide an additional layer of regulation by 
which mitogens regulate NOR1 expression.  
The normal medial SMC proliferate at a very low rate28. However, in response to 
mitogenic signals, SMC switch to a proliferative phenotype contributing to the 
development and progression of vascular diseases, such as atherosclerosis/restenosis28, 168. 
NOR1 has previously been demonstrated to be induced by PDGF in quiescent SMC, and 
its deficiency reduces SMC proliferation and neointima formation in a murine model of 
endothelium denudation94. In the present study, HDAC inhibition induces NOR1 
expression in quiescent SMC, suggesting that HDAC activity is required to prevent this 
mitogenic transcription factor from inappropriate activation in the normal vasculature. 
This effect was confirmed by transient transfection assays in which Scriptaid treatment 
increased NOR1 promoter activity in SMC. (Fig. 3A). Contrary to our findings, 
cAMP-activated NOR1 expression in PC12 cells has been reported to be suppressed by 
TSA, an HDAC inhibitor sharing a similar structure with Scriptaid, which might be due 
to the different cell line or stimulus used in that study169. In support of our findings, 
another NR4A member Nur77 has been reported to be induced by TSA169. In thymocytes, 
HDAC7 suppresses Nur77 expression which is increased by treatment with pan-HDAC 
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inhibitors170. Additionally, HDAC1 has been documented to be recruited to the Nurr1 
promoter to repress Nurr1 expression in unstimulated cells171. Collectively, these findings 
suggest that HDAC may serve as a general regulator of NR4A nuclear receptors to ensure 
their appropriate expression. Furthermore, it is worth noting that Scriptaid induced NOR1 
expression is much lower than co-stimulation with PDGF, linking the extracellular 
signals and chromatin modification in inducing NOR1 expression in SMC.  
Previous studies point to a critical role of CREB activation in inducing NOR1 
expression in vascular SMC94, hepatocytes69 and adipocytes77, demonstrating NOR1 as a 
CREB-responsive gene. The interaction of HDAC1/2 with phosphatase 1 (PP1) has been 
implicated in repressing cAMP-activated CREB-responsive gene expression by 
cooperatively mediating CREB dephosphorylation and histone deacetylation in the target 
promoters171. To test which HDAC is involved in controlling NOR1 promoter activation, 
we employed siRNA technology to knockdown HDAC1, HDAC2 or HDAC3 in SMC. 
Surprisingly, HDAC1 or HDAC2 knockdown did not affect PDGF-induced NOR1 
mRNA expression. By contrast, HDAC3 knockdown results in more than a 2-fold 
increase in NOR1 expression at both the basal level and after PDGF stimulation. These 
two studies suggest that the specificity of HDAC recruitment to a CREB target gene is 
influenced by the local chromatin structure within the promoter region. In support of our 
observation, HDAC6 has been shown to be recruited to the promoter of glucocorticoid 
receptor (GR) and repress GR expression by uncoupling the CREB responses172.  
As previously mentioned, NOR1 is a CREB responsive gene69, 77, 94. We next 
analyzed CREB phosphorylation and found that Scriptaid alone increased CREB 
phosphorylation and co-stimulation with PDGF further enhanced CREB phosphorylation 
at each time point examined in the Figure 3.4A. This observation is consistent with 
previous findings that HDACi TSA sustained CREB phosphorylation 173. However, TSA 
failed to increase CREB phosphorylation and gene transcription over the early time 
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points in that study, suggesting that cAMP activation is capable of inducing the maximal 
amount of CREB phosphorylation. Therefore, these distinct effects of HDAC inhibition 
in promoting CREB target gene transcription indicate that PDGF alone is insufficient to 
lead to maximal CREB phosphorylation and gene activation. Our observation confirmed 
previous findings that growth factors or stress signals are less effective in promoting 
CREB target gene transcription compared to cAMP agonist174, 175.  
HDAC inhibition has been demonstrated to increase histone acetylation which is 
associated with gene activation34, 38. In ChIP assays, HDACi scriptaid increased histone 
acetylation at the CRE sites within the NOR1 promoter, resulting in increased recruitment 
of phospho-CREB (Figure 4B and 4C). Scriptaid alone increased histone H3 acetylation 
and phospho-CREB recruitment to levels comparable to PDGF stimulation alone. 
However, PDGF co-stimulation after Scriptaid treatment only modestly increased histone 
acetylation, which indicates that HDAC inhibition alone maximally loosened chromatin. 
By contrast, phospho-CREB recruitment was highly increased by PDGF co-stimulation 
after scriptaid treatment. This indicates that although upstream signaling did not further 
relax chromatin structure, it is necessary for the enrichment of phospho-CREB 
availability in the nucleus. These experiments reinforce the necessity of upstream 
signaling for maximal CREB phosphorylation, recruitment and NOR1 transcription. 
HDAC substrates include a large amount of non-histone proteins and acetylation of 
these non-histone proteins has been shown to modulate their functionality and protein 
stability38. Many nuclear receptors are subjected to acetylation, which regulates their 
stability, ligand sensitivity and trans-activation ability159. Finally, NOR1 stability was 
demonstrated to be enhanced by scriptaid, indicating NOR1 as a HDAC substrate.  
In summary, our findings suggest that HDAC inhibition increases NOR1 expression 
at multiple levels, including gene transcription and protein stability. HDACi have been 
suggested to suppress smooth muscle cell proliferation and migration149, 150, serving as 
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potential therapeutic targets for treating vascular diseases driven by SMC proliferation. 
NOR1 has previously been demonstrated as a mitogenic transcription factor promoting 
SMC cell proliferation and survival160. Therefore, our studies may provide a potential 
target for further sensitizing smooth muscle cells to HDAC inhibition.
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Figure 3.1. NOR1 expression is enhanced by HDACi Scriptaid in VSMC 
(A-B) Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min, 
and subsequently stimulated with PDGF (25 ng/ml). NOR1 mRNA (A) and protein 
expression (B) were analyzed at the indicated time points. mRNA expression was 
normalized to RPL13A and expressed as mean ±  SEM fold increase over 
DMSO-untreated cells (*P < 0.05 vs. untreated; #P < 0.05 vs. DMSO). Cohybridization for 
GAPDH was performed to assess equal loading. The autoradiograms are representative of 
three independently performed experiments. (C) Quiescent RASMC were stimulated with 
Scriptaid (2 µg/ml) or DMSO for 0.5, 2, 6, 12 and 24 hr for NOR1 mRNA analyses. mRNA 
expression was normalized to RPL13A and expressed as mean ± SEM fold increase over 
untreated (UT) cells (*P < 0.05 vs. UT). Experiments were repeated at least three times in 
duplicate with different cell preparations.  
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Figure 3.2. siRNA-mediated knockdown of HDAC3 expression increases 
PDGF-induced NOR1 mRNA expression 
(A-B) RASMC were transiently transfected with HDAC1, HDAC2, HDAC3 or scrambled 
(scr) siRNA (50 nM) for 6 hours, and recovered in growth media overnight. Transfected 
cells were starved in 0.01% FBS DMEM for 48 hours and stimulated with PDGF (25 ng/ml) 
or vehicle (PBS) for 6 hours for mRNA analyses. The expression of HDAC1, HDAC2, 
HDAC3 and NOR1 was normalized to RPL13A and expressed as mean ± SEM fold 
increase over scr-siRNA-transfected vehicle-treated cells (*P < 0.05 vs. vehicle, #p < 0.05 
vs. scr-siRNA).  
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Figure 3.3. Scriptaid increases NOR1 promoter activity without affecting NOR1 
transcript stability 
(A) RASMC were transiently transfected with a luciferase reporter construct (2 µg) driven 
by a 1.7kb NOR1 promoter and stimulated with DMSO or Scriptaid (2 µg/ml) overnight. 
Protein lysate was collected and analyzed for luciferase activities. Data were normalized to 
renilla luciferase activities and presented as mean ± SEM from three independently 
performed experiments (*p < 0.05 vs. DMSO). (B) Quiescent RASMC were pretreated 
with Scriptaid (2 µg/ml) or DMSO for 30 min and subsequently stimulated with PDGF (25 
ng/ml) for 2 hours. Actinomycin D (10 µg/ml) was added to inhibit transcription and 
mRNA was collected at the indicated time points. NOR1 mRNA expression was 
normalized to RPL13A from three independent experiments. Data are expressed as mean ± 
SEM fold increase over the samples stimulated with PDGF for 2 hr. N.S. indicates that no 
statistical significance was detected between DMSO and Scriptaid treatments.  
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Figure 3.4. Scriptaid enhances CREB phosphorylation and the recruitment of 
phospho-CREB to its binding sites in the NOR1 promoter 
(A) Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min and 
subsequently stimulated with PDGF (25 ng/ml) for 0.5, 1 and 3 hr for protein analyses. 
Cohybridization for total CREB was performed to assess equal loading. The 
autoradiograms are representative of three independently performed experiments. (B-C) 
Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min and 
subsequently stimulated with PDGF (25 ng/ml) for 1 hr for ChIP assays. Chromatin 
complexes were immunoprecipitated with antibodies against phospho-S133 CREB, 
AcH3K9, and species-matched IgG. PCR products were amplified using primers covering 
the CRE sites from -79 bp to -46 bp in the NOR1 promoter. The agarose gels shown are 
representative of three independently performed experiments.  
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Figure 3.5. HDAC inhibitor Scriptaid increases NOR1 protein stability  
(A-B) Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min 
and subsequently stimulated with PDGF (25 ng/ml) for 6 hours. Cycloheximide (CHX, 10 
µg/ml) was added to inhibit protein synthesis and protein was collected at the indicated 
time points. (A) The autoradiograms are representative of three independently performed 
experiments. Cohybridization for GAPDH was performed to assess equal loading. (B) 
Densitometric quantification of NOR1 expression was performed from three independent 
experiments and normalized to GAPDH expression. Results are expressed as mean ± SEM 
fold increase over samples treated with PDGF for 6 hr. (*p < 0.05 vs. PDGF 6 hr, # p < 0.05 
vs. DMSO).  
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Chapter four: General discussion 
4.1. Discussion 
4.1.1. Summary 
The primary goal of this study is to understand the role of the NR4A3 orphan 
nuclear receptor (NR) NOR1 in the development of atherosclerosis. We demonstrate that 
NOR1 is highly expressed in human atherosclerotic lesions, while NOR1 expression is 
absent in the normal vasculature. In advanced atherosclerotic lesions, NOR1 expression 
co-localizes with endothelial and sub-endothelial cells. Following experiments performed 
in this study focus on the regulation of NOR1 expression in endothelial cells and smooth 
muscle cells, and the significance of NOR1 in the development of atherosclerosis. In 
endothelial cells we demonstrate that NOR1 expression is rapidly and potently induced 
by several pro-inflammatory factors through an NF-κB dependent signaling pathway. 
Functional analyses point to a previously unrecognized role of NOR1 in promoting 
monocyte adhesion by increasing VCAM-1 and ICAM-1 expression in endothelial cells. 
Consistently, NOR1 deficiency decreased atherosclerosis formation in a 
hypercholesterolemia mouse model. Quantitative macrophage staining reveals reduced 
macrophage accumulation in the NOR1-deficient atherosclerotic lesions. In smooth 
muscle cells (SMC), NOR1 expression is induced by mitogenic stimulation, and this 
effect is further enhanced by HDAC inhibition. Mechanistic studies demonstrate that 
HDAC inhibition increases NOR1 expression by promoting NOR1 mRNA transcription 
and protein stability. In summary, this study has demonstrated that NOR1 acts as an 
atherogenic transcriptional regulator promoting monocyte-endothelial cell adhesion, and 
has provided mechanisms for the epigenetic control of mitogen-induced NOR1 
expression in SMC. In the following discussion of my dissertation, I will further discuss 
the role of NOR1 in vascular diseases, focusing on the concepts not mentioned in 
previous chapters as well as the relationship to its NR4A siblings Nur77 and Nurr1. 
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Finally, I will discuss some of my own understandings regarding the significance of NRs 
in the prevention of cardiovascular diseases. 
4.1.2. The role of NOR1 in endothelial cells 
Activation of several NR has been reported in endothelial cells176-185. PPARα and 
PPARγ are the best studied NRs in endothelial cells and PPAR activation has been 
implicated in endothelial cell activation, proliferation and survival176-181, 183. In addition to 
ligand-activated nuclear receptors177, 186, an increasing number of studies have pointed to 
the significance of orphan NR, including COUP-TFII185, retinoic acid receptor 
(RAR)-related orphan nuclear receptor α (RORα) 182 and NR4A NR160, in regulating 
endothelial cell proliferation and inflammation. 
In Chapter two, we demonstrate in endothelial cells that NOR1 is induced by 
inflammatory cytokines and enhances monocyte adhesion by increasing VCAM-1 and 
ICAM-1 expression. We performed transient transfection assays and ChIP assays 
showing that NOR1 activates VCAM-1 transcription by directly binding to the NBRE 
site in the NOR1 promoter. However, mutations introduced into the NBRE site did not 
completely abolish the VCAM-1 promoter activity induced by NOR1 over-expression 
(Figure 2.6B), indicating that other transcriptional regulators may be involved in 
VCAM-1 trans-activation.  
Several studies have revealed that NR also function as co-regulators modulating 
gene expression through interacting with other transcription factors187, 188. Both NF-κB 
and AP-1 are critical transcription factors regulating VCAM-1 expression during 
endothelial activation/dysfunction189-191. Therefore, it is intriguing to understand whether 
NOR1 promotes NF-κB/AP-1-dependent transcription activation. Preliminary 
experiments were performed in endothelial cells by transiently transfecting luciferase 
reporter constructs driven by multiple NF-κB/AP-1 response elements. Interestingly, 
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NOR1 over-expression increased the promoter activity of plasmids driven by NF-κB 
response elements, while no induction was observed on plasmids driven by AP-1 
response elements (Figure 4.1A and B). NF-κB proteins are ubiquitously expressed in 
many cell types and they are sequestered in the cytoplasm by binding to the inhibitor of 
NF-κB (IκB) in unstimulated cells. NF-κB is activated by a series of phosphorylation 
reactions which ultimately lead to IκB degradation and release of NF-κB to the 
nucleus192. We first analyzed whether NOR1 expression induces NF-κB nuclear 
translocation in endothelial cells. As described in Figure 4.1C, NOR1 over-expression 
exhibited no apparent effect on NF-κB nuclear enrichment when evaluated by p65 
immunostaining. Another possibility relies on the direct interaction between NOR1 and 
NF-κB. Immunoprecipitation (IP) assays demonstrated an interaction between NOR1 and 
NF-κB p65 (Figure 4.1D), thus indicating that NOR1 may interact with NF-κB in the 
nucleus and stabilize the binding of NF-κB to its promoters. Future experiments need to 
be performed to demonstrate the co-recruitment of NOR1 to the NF-κB binding sites in 
the VCAM-1 promoter. In support of our observation, AP-1 transcription factors c-Fos 
and c-Jun have been shown to interact with NF-κB and enhance VCAM-1 
trans-activation in endothelial cells193. 
By contrast, other NR, such as PPARγ, estrogen receptor (ER), and glucocorticoid 
receptor (GR), have been implicated in the repression of VCAM-1 expression in 
endothelial cells by suppressing NF-κB/AP-1 dependent trans-activation194, 195. Nur77, an 
NR4A orphan NR sharing high protein sequence homology with NOR1, has recently 
been shown to repress VCAM-1 and ICAM-1 expression in endothelial cells by 
increasing the expression of NF-κB inhibitor IκBα104. This study suggests a novel 
mechanism that NR repress adhesion molecule expression by interfering with NF-κB 
upstream signaling pathway. However, we did not observe any evidence of increased 
IκBα expression by NOR1 in our study (data not shown). These seemingly opposing 
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findings suggest that Nur77 and NOR1 may interact with different co-factors to regulate 
target gene expression. 
In addition, PPARα has been shown to interfere with AP-1/NF-κB-dependent IL-6 
transcription by physically interacting with c-Jun and p65 in vascular SMC196. Activation 
of Liver X receptors (LXR) suppresses matrix metalloproteinase (MMP)-9 expression 
through antagonizing the NF-κB signaling pathway in macrophages197. Recently, NR4A 
nuclear receptor Nurr1 was shown to dock to NF-κB-p65 resulting in NF-κB clearance 
and trans-repression of inflammatory gene expression in microglia and astrocytes60. 
Therefore, the involvement of NR in NF-κB transcription complexes likely serves as a 
general mechanism, by which NR regulate transcriptional responses to inflammatory 
signaling. While most studies point to a NR-mediated trans-repression mechanism, our 
findings have provided evidence that NF-κB target gene expression could be modulated 
through a trans-activation mechanism. 
4.1.3. The role of NOR1 in vascular smooth muscle cells 
Atherosclerosis progression is associated with SMC migration into the arterial intima. 
Intimal SMC are characterized by an accelerated proliferation rate and greater synthetic 
capability, while normal medial SMC exhibit a contractile phenotype maintaining a 
quiescent state. HDAC inhibitors (HDACi) have been used in clinical trials as novel 
anticancer agents due to their beneficial effect on promoting cell differentiation, growth 
arrest, and apoptosis of tumor cells145, 148. In addition, recent discovery has shown that 
HDACi exhibit beneficial effects in vascular cells. HDAC inhibition represses vascular 
SMC proliferation and prevents mechanically induced vascular SMC migration149, 150, 164. 
Consistent with these observations, our preliminary data show that HDACi Scriptaid 
increases apoptosis in quiescent SMC (Figure 4.2). 
We have previously demonstrated that NOR1 plays a critical role in promoting SMC 
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survival and mitogen-induced proliferation95. In Chapter three, we demonstrate that 
HDACi Scriptaid and PDGF synergistically increase NOR1 expression in SMC. 
Therefore, Scriptaid-induced NOR1 expression may impair the efficacy of HDAC 
inhibition and attenuate HDACi-induced SMC apoptosis/growth arrest. In fact, HDACi 
resistance has been previously investigated and the underlying mechanisms involve 
up-regulation of antioxidant pathways and increased expression of anti-apoptotic 
proteins148, 198. Experiments in which Scriptaid-induced apoptosis is compared between 
NOR1 wildtype and deficient SMC may provide some insight on the role of NOR1 in 
HDACi resistance. Silencing or suppressing NOR1 expression may increase SMC 
sensitivity to HDACi induced apoptosis/growth arrest, hence potentiating the efficacy of 
HDACi for treating vascular diseases primarily driven by SMC proliferation.  
Statins, which are used in clinical trials for treating cardiovascular diseases by 
reducing plasma LDL-cholesterol levels, have shown some promise by reducing 
LDL/hypercholesterolemia-induced NOR1 expression in SMC and aortae107. More 
interestingly, statins have recently been demonstrated as novel HDAC inhibitors199. 
Computational modeling and immunoprecipitation assays provided evidence suggesting 
that the carboxylic acid moiety of statins directly targets the catalytic site of HDAC 
thereby inhibiting the activities of HDAC1-3. These findings challenged our observations 
in Chapter three and raised the question of how statins inhibit HDAC activity yet also 
repress NOR1 expression. One possible explanation resides in the disrupted CREB 
phosphorylation by statins. Although statins can increase histone acetylation creating 
looser chromatin structure, the lack of phospho-CREB may account for the repression of 
NOR1 expression. This is reminiscent of our observation that HDAC inhibition alone 
only induces NOR1 expression modestly, while maximal NOR1 expression relies on the 
abundance of phospho-CREB. These seemingly contradictory findings emphasize the 
importance and necessity to investigate the epigenetic control of NOR1 expression. 
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4.1.4. The role of NOR1 in atherosclerosis development 
The expression of NR4A nuclear receptors has been implicated in vascular diseases 
including atherosclerosis, restenosis and vascular remodeling160, 200. In vivo studies show 
that Nur77 or Nurr1 over-expression in SMC decreases lesion formation in a carotid 
artery ligation model by restricting SMC proliferation91, 201. This repressive effect is 
potentiated by 6-mercaptopurine, an antineoplastic agent mediating the activation of 
NR4A nuclear receptors, in a mouse model of cuff-induced neointima formation202. 
Nur77 over-expression in SMC also protects against vascular outward remodeling by 
reducing macrophage accumulation and MMP expression203. Additionally, NR4A 
receptors have been shown to repress the expression of inflammatory cytokines and lipid 
loading in macrophages97. Together, these studies point to a protective role of Nur77 and 
Nurr1 in reducing vascular SMC proliferation and macrophage inflammation. 
Conversely, opposing regulatory effects of NR4A receptors have been suggested by 
other studies. Nur77 over-expression increases inflammatory signaling in macrophages 
and endothelial cells99, 116. In addition, NOR1 promotes SMC survival and proliferation 
and its deficiency reduces neointima formation in a murine endothelium denudation 
model95. Nonetheless, direct evidence is still lacking with regard to the role of NR4A 
receptors in atherosclerosis development. 
Based on our findings in Chapters two and three, NOR1 expression in endothelial 
cells increases monocyte adhesion and mediates mitogen-induced cell proliferation in 
smooth muscle cells. Hence, we hypothesized that NOR1 functions as an atherogenic 
transcriptional regulator in the vascular wall. To investigate our hypothesis, 
NOR1-/-apoE-/- mice were generated to create a hypercholesterolemia background to 
study the role of NOR1 in atherosclerosis development. As expected, NOR1 deficiency 
decreases atherosclerosis formation accompanied by reduced macrophage accumulation 
in the sub-endothelial space.  
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However, it is worth noting that NOR1 deficiency only partially blocked 
atherosclerosis formation. Although macrophage accumulation is reduced in NOR1 
deficient lesions, significant amount of macrophages are still readily detectable in the 
arterial intima. One possible explanation may reside in the excessive leukocytosis in 
NOR1 deficient mice (Figure 4.3A). The leukocytosis in NOR1-deficient mice is 
primarily due to increased monocyte, lymphocyte, and granulocyte numbers in the 
absence of changes in red blood cell counts. Studies have demonstrated that monocyte 
recruitment is mediated by different adhesion molecules on the endothelial cell surface7. 
As proposed in this study, NOR1 deficiency reduces monocyte adhesion via VCAM-1 
and ICAM-1. However, the reduction of monocyte adhesion could be impaired due to 
increased monocyte availability in the blood. In addition, a large amount of evidence 
supports the presence of T lymphocytes and granulocytes in the atherosclerotic lesions, 
which contributes to atherosclerosis development and progression17, 18, 204, 205. Increased 
lymphocyte and granulocyte numbers may also account for the residual lesions seen in 
the NOR1-deficient mice.   
Our preliminary experiments also showed that NOR1-deficient leukocytes isolated 
from the peritoneal cavity after thioglycollate injection are more susceptible to apoptosis 
compared to NOR1 wildtype peritoneal cells (Figure 4.3B). This indicates that 
NOR1-deficient leukocytes are defective in clearing exotoxins or surviving immune 
insults. Recently, the concept inflammation resolution has drawn increasing attention and 
has provided new insights in the treatment of atherosclerosis23. One key step in resolving 
inflammation in atherosclerotic plaques is efferocytosis of apoptotic inflammatory cells23. 
The major effectors of efferocytosis include macrophages and dendritic cells23. It is very 
likely that NOR1-deficent macrophages/dendritic cells are less efficient in clearing 
apoptotic/dead inflammatory cells in the vascular wall, which will ultimately result in the 
accumulation of apoptotic macrophages and aggravation of inflammatory responses. For 
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that reason, it would be helpful to analyze the efferecytosis ability of NOR1-deficient 
monoyctes/macrophages and compare their viability in response to proatherogenic 
stimuli. 
In order to understand whether NOR1 deficiency results in increased macrophage 
accumulation, several approaches may be considered. One experiment is bone marrow 
transplantation, in which NOR1-deficient and wildtype bone marrow cells are 
transplanted to lethally irradiated apoE-/- mice. Based on our hypothesis, mice 
transplanted with NOR1-deficient bone marrow cells will develop more atherosclerosis 
than mice transplanted with NOR1-wildtype bone marrow. However, bone marrow cells 
are highly heterogeneous, consisting of hematopoietic stem cells and progenitor cells at 
various differentiation stages. As an alternative, mice with tissue-specific NOR1 
knockdown in the monocyte-macrophage lineage will serve as a better strategy. 
Furthermore, mice with specific NOR1 knockdown in endothelial cells will confirm our 
previous findings that NOR1 deficiency decreases atherosclerosis formation by blocking 
monocyte adhesion. In summary, these studies will provide a better understanding of the 
mechanisms by which NOR1 promotes atherosclerosis. 
4.1.5. Implications for the prevention of cardiovascular diseases 
Numerous studies have been performed in order to provide potential targets for the 
prevention and treatment of cardiovascular diseases. Many nuclear receptors have shown 
beneficial effects in the vasculature. The activation of PPARα by synthetic agonists 
reduces cardiovascular disease by improving lipid homeostasis206. PPARγ, which was 
originally used for increasing insulin sensitivity, also reduces a wide range of 
cardiovascular risk factors, including inflammatory cytokines, adipokines and free fatty 
acids207. LXR are key transcriptional regulators controlling cholesterol metabolism and 
promoting reverse cholesterol transport in macrophages208. In vivo studies have shown 
that activation of LXR plays a protective role in atherosclerosis development in mouse 
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models208-211. In addition, estrogen receptors and glucocorticoid receptors have shown 
some vasoprotective effects by repressing inflammatory signaling212, 213.  
The activation/repression of NR by the binding of small molecules has proved 
advantageous for the treatment of cardiovascular diseases. In this study, we demonstrate 
that decreased NOR1 expression in the vasculature protects against atherosclerosis 
development163. However, the lack of a typical ligand-binding pocket in the NOR1 
protein considerably limits the possibility of using small molecules to suppress NOR1 
transcriptional activity51. In addition, induced NOR1 expression in other tissues has been 
shown to be indispensible for maintaining normal physiological functions69, 77, 78, 89. In 
response to starvation, NOR1 increases gluconeogenesis in the liver69. In the skeletal 
muscle, NOR1 enhances oxidative metabolism77 and glucose uptake78. NOR1 also plays 
a critical role in regulating thermogenesis in the adipose tissue89. Furthermore, our 
preliminary data showed that NOR1 deficiency resulted in an increase in the body weight 
when NOR1+/+ and NOR1-/- mice were fed a chow diet (data not shown). Therefore, 
unless tissue specific modulators are developed, NOR1 suppression by antagonists may 
result in unpredictable side effects on the normal processes of metabolism.  
These two challenges raise the question of the implications of our studies on the 
role of NOR1 in atherosclerosis development. NOR1 can be induced by a variety of 
cardiovascular risk factors, such as hypercholesterolemia and inflammatory cytokines160, 
and plays an atherogenic role in the vascular wall. Therefore, a tight control on these risk 
factors may reduce the possibility and magnitude of NOR1 induction and protect against 
atherosclerosis. For example, fat constitutes an important component in our daily diet. 
Dietary fat has a great impact on the plasma lipoprotein profile, which is a key factor in 
mediating atherosclerosis development214. Long-chain saturated fatty acids (LC-SFA), 
but not long-chain un-saturated fatty acids (LC-USFA) or short-chain fatty acids (SC-FA), 
have been shown to activate NF-κB and promote inflammatory gene expression in 
endothelial cells215, 216. Our studies demonstrate NOR1 as an NF-κB target gene in 
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endothelial cells, indicating that NOR1 is likely to be induced by LC-SFA163. In smooth 
muscle cells, NOR1 can be induced by low density lipoprotein (LDL), a key risk factor in 
the onset of atherosclerosis106. By contrast, USFAs tend to improve the lipoprotein profile 
by decreasing LDL cholesterol levels214. Omega-3 fatty acids have been shown to repress 
endothelial activation by reducing NF-κB activation217. Collectively, these studies 
indicate that limiting the amount of LC-SFAs in the diet may provide beneficial effects 
on reducing NOR1 expression in endothelial cells and smooth muscle cells. A diet with a 
higher percentage of USFA will be favorable in reducing cardiovascular risk by 
improving plasma lipoprotein profiles and thereby suppressing NOR1 expression in the 
vascular wall. 
4.2. Perspectives 
As investigated and discussed in this study, the ligand-independent NR4A3 orphan 
nuclear receptor NOR1 functions as an immediate early response gene. All cell types 
participating in vascular diseases rapidly induce NOR1 expression in response to arterial 
injury. Our in vivo studies using a murine hypercholesterolemia model demonstrate NOR1 
as an atherogenic transcriptional regulator. Nevertheless, several key questions still need to 
be answered. All the NR4A nuclear receptors bind to the same NBRE site, which is 
indicative of functional redundancy among these NR4A members. However, deficiency of 
any NR4A nuclear receptor is associated with an apparent phenotype (NOR1 deficiency 
decreases atherosclerosis163, Nur77 deficiency impairs insulin sensitivity76, Nurr1 
deficiency results in neonatal lethality218), demonstrating that each NR4A member has 
specific functions which cannot be compensated by the other two siblings. In addition, an 
intriguing question is what are the distinct roles of NOR1 in endothelial cells and 
monocytes/macrophages with relevance to regulating atherosclerosis development? 
Another important question for future investigation is how to reconcile the distinct 
biological effects of NOR1 and Nur77/Nurr1 in vascular cells and the development of 
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atherosclerosis? In order to answer these questions, a key emphasis of future research is to 
identify NR4A target genes and define the genome-wide pattern of NR4A chromatin 
occupancy. In addition, advances in understanding NR4A posttranslational modifications 
and co-activator/co-repressor recruitment will help establish detailed transcriptional 
networks by which NR4A receptors control vascular gene expression programs. Continued 
investigation of these questions will provide new insights into how these NR4A receptors 
participate in the processes of normal metabolism and the development of cardiovascular 
diseases. 
4.3. Conclusion 
In this study, we have performed extensive studies and made substantial progress in 
understanding the regulation of NOR1 expression in endothelial cells and smooth muscle 
cells. We further identified VCAM-1 as a bona fide NOR1 target gene in endothelial cells. 
In vivo studies using a murine model of hypercholesterolemia provide initial evidence 
characterizing NOR1 as an atherogenic transcriptional regulator. Increased NOR1 
expression in response to HDAC inhibition suggests NOR1 may contribute to HDACi 
resistance in smooth muscle cells. Therefore, manipulation of NOR1 expression may 
provide some insight into therapeutic treatment for vascular diseases such as 
atherosclerosis and restenosis. 
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Figure 4.1. NOR1 increases NF-κB-dependent transcription activation by 
interacting with NF-κB p65 without affecting p65 translocation 
(A-B) HUVEC were transiently transfected with luciferase reporter constructs (0.5 µg) 
driven by multiple NF-κB/AP-1 response elements. Cells were co-transfected with NOR1 
or GFP expression vector (0.5 µg) and recovered overnight following transfection. Protein 
lysate was collected and analyzed for luciferase activities. Data were normalized to renilla 
luciferase activities and presented as mean ± SEM (*p < 0.05 vs. pCMV-GFP). (C) 
HUVEC were infected with 50 PFU Ad-CMV-NOR1 or Ad-CMV-Null as control. Infected 
cells were immunostained for NF-κB p65. Images were acquired using confocal 
microscopy (objective magnification x200). Stainings for p65 and DAPI were merged into 
one image as indicated. (D)  HEK293 cells were transiently transfected with NOR1 and 
p65 over-expression vectors (2 µg) and recovered for 24 hours. Cell lysates were collected 
and immunoprecipitated with an antibody against p65 (5 µg). Precipitates were subjected 
to SDS–PAGE and immunoblotted with indicated antibodies. 
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Figure 4.2. HDAC inhibition increases smooth muscle cell apoptosis 
Quiescent human coronary smooth muscle cells were stimulated with Scriptaid (2 µg/ml) 
or DMSO for 2 days. Cells were then collected and subjected to annexin V and propidium 
iodide (PI) staining and apoptosis was quantified using fluorescence activated cell sorting 
(FACS). Data are presented as mean ± SEM (*p < 0.05 vs. DMSO). 
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Figure 4.3. NOR1 deficiency increases leukocytosis and leukocyte apoptosis in the 
peritoneal cavity 
(A) 6 NOR1+/+ and 6 NOR1-/- mice (8-12 weeks old) were used for this study. Blood was 
drawn from the mouse retro-orbital sinus and blood cell count was assessed using a 
Hemavet cell counter. Data were presented as mean ± SEM (*p < 0.05 vs. NOR1+/+). (B) 
6 NOR1+/+ and 6 NOR1-/- mice (8-12 weeks old) were injected intraperitoneally with 3 
ml thioglycollate media (3 %). 3 days after injection, peritoneal cells were isolated in 6 ml 
PBS by peritoneal lavage and subjected to annexin V and PI staining. Apoptosis was 
analyzed using fluorescence activated cell sorting (FACS). Data are presented as mean ± 
SEM (*p < 0.05 vs. NOR1+/+). 
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Appendices 
Appendix A. Methods 
1. Whole cell lysate collection and Western blotting 
(1) Whole cell lysate collection 
 Perform each step on ice 
 Rinse the cell monolayer twice with ice-cold phosphate buffered saline (PBS) 
 Remove the remaining PBS completely 
 Add 100 µl/ 10 cm cell culture plate of 1x ice-cold lysis buffer (Cell Signaling) 
containing 1 % protease inhibitor cocktail (Sigma) 
 Collect cells in a 1.5 ml eppendorf tube using cell lifters 
 Homogenize by vortexing and sitting in ice for 10 min 
 Centrifuge at 13,000 rpm, 4 °C for 15 min 
 Transfer the supernatant to a fresh tube, and proceed to the next step 
 (2) Protein concentration measurement 
 Measure protein concentration using the Bio-Rad DC Protein Assay Reagents 
Package containing Reagents A, B and S 
 Prepare dilutions of Bovine Serum Albumin (BSA) Standard (2 mg/ml) in 1.5 ml 
eppendorf tubes as follows: 
Dilution 2 mg/ml BSA Distilled H2O 
S1, 0 mg/ml  25 µl 
S2, 0.16 mg/ml 2 µl 23 µl 
S3, 0.32 mg/ml 4 µl 21 µl 
S4, 0.8 mg/ml 10 µl 15 µl 
S5, 1.0 mg/ml 12.5 µl 12.5 µl 
S6, 1.2 mg/ml 15 µl 10 µl 
 Prepare protein dilutions by adding 2.5 µl protein to 10 µl distilled H2O 
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 Prepare dye reagent by diluting 25 µl Reagent S in 1 ml Reagent A 
 Pipette 5 µl standards (S0-S6) and sample dilutions in duplicate to a 96 well plate 
 Pipette 25 µl dye reagent into each well 
 Pipette 200 µl Reagent B into each well 
 Measure absorbance at 595 nm using a microplate reader  
(3) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 1x Electrode buffer 
Tris Base 3.03 g 
Glycine 14.4 g 
SDS 1 g 
Distilled H2O to 1 L 
 1x Transfer Buffer  
Tris Base 4.64 g 
Glycine 2.32 g 
Methanol 160 ml 
10 % SDS 3 ml 
Distilled H2O 640 ml 
Total 800 ml 
 10x TBS 
Tris Base 24.2 g 
NaCl 80 g 
Adjust pH to 7.6 with HCl ~ 10 ml 
Distilled H2O To 1 L 
 1x TBST 
10x TBS 100 ml 
Tween-20 1 ml (0.1 %) 
Distilled H2O To 1 L 
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 Separating Gel, 7.5 %, 15 mm (for 2 gels) 
Distilled H2O 6.8 ml 
1.5 M Tris-HCl, pH 8.8 3.5 ml  
10 % SDS 140 µl 
30 % Acrylamide/Bis 3.5 ml 
10 % Ammonium Persulfate (APS) 100 µl 
TEMED 20 µl 
Total 14 ml 
 Stacking Gel, 15 mm (for 3 gels) 
Distilled H2O 5.5 ml 
0.5 M Tris-HCl, pH 6.8 2.25 ml  
10 % SDS 90 µl 
30 % Acrylamide/Bis 1.2 ml 
10 % Ammonium Persulfate (APS) 60 µl 
TEMED 10 µl 
Total 9 ml 
 Load 40 µg protein/ well 
 Run the gel at 50 V for 1 hour and switch to 100 V for 1.5 hours 
 Transfer proteins onto the nitrocellulose membrane (GE Healthcare Life Sciences) 
 Transfer proteins at 100 V for 2 hours 
(4) Western blotting 
 Block the membrane in 5 % fat-free milk/ TBST buffer at room temperature (RT) for 
1 hour 
 Add primary antibody (1:1000 v/v dilution) and incubate the membrane on shaker at 
4 °C overnight 
 Rinse the membrane with 1x TBST for 5 min on shaker 
 Repeat the last step twice with fresh TBST 
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 Bind secondary antibody (1:2000 v/v dilution) in 5 % milk/ TBST buffer at RT for 
1.5 hours 
 Rinse the membrane with 1x TBST for 5 min on shaker 
 Repeat the last step 4 times with fresh TBST 
 Visualize target proteins with autoradiography using Amersham ECLTM Western 
Blotting Detection Reagents (GE Healthcare Life Sciences) 
2. RNA isolation and Quantitative reverse transcription polymerase chain reaction 
(RT-PCR) 
(1) RNA isolation and RNA concentration measurement 
 Rinse the cell monolayer with PBS and remove the remaining PBS completely 
 Add 1ml Trizol (Invitrgen)/ 10 cm cell culture plate 
 Homogenize cells by pipetting up and down for a few times and transfer the cell 
lysate to a fresh 1.5 ml tube 
 Isolate RNA according to the manufacture’s instruction 
 Resuspend RNA in diethyl pyrocarbonate (DEPC) treated water 
 Incubate in a water bath at 55°C for 10 min 
 Measure RNA concentration using an NanoDrop Spectrophotometer 
(2) RT-PCR 
 Synthesize first-strand cDNA using SuperScript™ II RT (Invitrogen) 
 Set up a 20-µL reaction volume on ice using 1 µg total RNA as follows: 
Random primers (500 ng/ml) 1 µl 
dNTP mixture (10 mM each) 1 µl 
RNA 1 µg 
Sterile distilled H2O To 13 µl 
 Heat the mixture to 65°C for 5 min and quick chill on ice. Collect the contents of the 
tube by brief centrifugation and add: 
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5x First-Strand Buffer 4 µl 
0.1 M DTT  2 µl 
 Mix contents gently and incubate the mixture at RT for 2 min 
 Add 1 µl SuperScript™ II RT and mix by pipetting gently up and down 
 Perform RCP reactions on a thermocycler using the following PCR cycles: 
25 °C 10 min 
42 °C 50 min 
70 °C 15 min 
 cDNA can be stored at 4 °C for a short period or at -80 °C for long term storage 
(3) Realtime-PCR 
 Dilute cDNA by 1:50 in sterile distilled water 
 Set up a 25-µL reaction volume on ice using 10 µl diluted cDNA as follows: 
Diluted cDNA 10 µl 
Forward primer (10 µM) 0.5 µl 
Reverse primer (10 µM) 0.5 µl 
iQTM SYBR Green Supermix (BioRad) 12.5 µl 
Sterile distilled water 1.5 µl 
 Perform RCP reactions on an iCycler (Bio-Rad) using the following PCR cycles: 
Cycle 1 (1x) 95 °C 10 min 
Cycle 2 (40x) 95 °C 30 sec 
 55 °C 30 sec 
 72 °C 30 sec 
Cycle 3 (1x) 72 °C 10 min 
Cycle 4 (1x) 10 °C forever 
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(4) Primers used for realtime-PCR in this study 
Name  Sequence  
human NOR1 
F : 5’-GGGCTTTTTCAAGAGAACAGTG-3’  
R: 5’-ATCTCTGGGTGTTGAGTCTGTT-3’ 
human VCAM-1 
F: 5’-TGAGGGGACCAATTCCAC-3’ 
R: 5’-ATTCACGAGGCCACCACT-3’ 
human ICAM-1 
F: 5’-ACCGTGAATGTGCTCTCC-3’ 
R: 5’-GGCTTGTGTGTTCGGTTT-3’ 
murine VCAM-1 
F: 5’-TCAAAGAAAGGGAGACTG-3’ 
R: 5’-GCTGGAGAACTTCATTATC-3’ 
murine ICAM-1 
F: 5’-AGATCACATTCACGGTGCTG-3’ 
R: 5’-CTTCAGAGGCAGGAAACAGG-3’ 
human TBP  
F: 5’-GGAGAGTTCTGGGATTGTACCGC-3’ 
R: 5’-ATATTCGGCGTTTCGGGCAC-3’ 
murine TFIIB 
F: 5’-CTCTCCCAAGAGTCACATGTCC-3’ 
R: 5’-CAATAACTCGGTCCCCTACAAC -3’ 
murine NOR1 
F: 5’-GGCCGCAGCTGCACTCAGTC -3’ 
R: 5’-GCGGAGGGAAGGTCAGCGTG -3’ 
murine Nur77 
F: 5’-TTGATGTTCCCGCCTTTG-3’ 
R: 5’-GGTAGCCATGTGCTCCTTC-3’ 
murine Nurr1 
F: 5’-TCACCTCCGGTGAGTCTGATC-3’ 
R: 5’-TGCTGGATATGTTGGGTATCATCT-3’ 
rat NOR1 
F: 5’-CAGCAGCTGCGAACTCAA-3’ 
R: 5’-CGGTGTAGAAGGCGGAGA-3’ 
rat RPL13A 
F: 5’GTACGCTGTGAGGGCATCAA-3’ 
R: 5’-CTCGAGACGGGTTGGTGTTC-3’ 
rat HDAC1 
F: 5’-CCATCAAAGGACATGCCAAGT-3’ 
R: 5’-CGAGCGACATTACGGATGGT-3’ 
rat HDAC2 
F: 5’-CGGCAAGAAGAAAGTGTGCTACT-3’ 
R: 5’-ATGAGTCATCCGGATCCTATGG-3’ 
rat HDAC3 
F: 5’-GCACCCGCATCGAGAATC-3’  
R: 5’-TGGACACTGGGTGCATGGT-3’ 
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3. Immunostaining of OCT-embedded frozen sections 
 Heat slides in heated distilled water for 2 minutes and dry slides at RT 
 Fix tissues in chilled acetone at -20 °C for 1 min 
 Incubate in 0.5 % Triton X-100/ PBS at 40 °C for 10 min 
 Incubate in Redusol at 40 °C for 2 min 
 Incubate in automation buffer at RT for 1 min 
 Rinse slides with automation buffer 4 times at RT 
 Incubate in DAKO Blocking Reagent at 40 °C for 5 min 
 Rinse with automation buffer twice at RT 
 Dilute primary antibody in Dako Antibody Diluent (typically 1: 100 dilution) 
 Bind primary antibody at 40 °C for 15 min 
 Rinse slides with automation buffer 5 times at RT 
 Dilute biotinylated secondary antibody in Dako Antibody Diluent (typically 1: 200 
dilution) 
 Bind secondary antibody at 40 °C for 15 min 
 Rinse with automation buffer 5 times at RT 
 Amplify antigen-antibody interaction using the Avidin-Biotin Complex (ABC) 
(Vector Laboratories) at 40 °C for 10 min 
 Rinse with automation buffer 5 times at RT 
 Visualize signals by chromogen red 3-amino-9-ethylcarbazole (AEC) (Biomeda Corp) 
at 40 °C for 10 min 
 Repeat the last step if necessary 
 Rinse slides with distilled water twice at RT 
 Flush slides with hematoxylin for nuclei visualization 
 Mount slides in glycerol with a coverglass  
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4. Transient transfection assays 
(1) Transient transfection of human endothelial cells using promofectin-HUVEC 
(PromoKine) 
 Seed cells at 15x 104 / well in 6-well plates 24 hours before experiment 
 Dilute 4 µl promoter constructs (0.5 µg/ml) for each transfection in 25 µl 
Opti-MEM® I Reduced Serum Medium (Opti-MEM) (Invitrogen), and mix well by 
vortexing for 10 sec 
 Dilute 4 µl promofectin for each transfection in 25 µl Opti-MEM, and mix well by 
vortexing for 10 sec 
 Mix DNA and promofectin dilutions and vortex the mixture for 10 sec 
 Incubate the mixture at RT for 20 min  
 While the mixture is incubating, wash the endothelial cells once with PBS and add 2 
ml/ well fresh Opti-MEM 
 Add 50 µl/ well of the promofectin / DNA solution to the cells and shake the plate 
gently 
 Incubate at 37 °C for 3 hours 
 Wash the cells three times with PBS and add 2 ml/ well fresh growth media 
(2) Transient transfection of rat aortic smooth muscle cells using lipofectamine 2000 
(Invitrogen) 
 Seed cells at 20x 104 / well in 6-well cell culture plates 24 hours before experiment 
 Dilute 4 µl promoter constructs (0.5 µg/ml) for each transfection in 250 µl 
Opti-MEM, and mix well by vortexing for 10 sec 
 Dilute 6 µl lipofectamine 2000 for each transfection in 250 µl Opti-MEM, mix well 
by vortexing for 10 sec and incubate at RT for 5 min 
 Mix DNA and lipofectamine 2000 dilutions and vortex the mixture for 10 sec 
 Incubate the mixture at RT for 20 min 
 While the mixture is incubating, add 2 ml/ well 5 % FBS DMEM without antibiotics 
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 Add the lipofectamine / DNA solution to the cells and shake the plate gently 
 Incubate at 37 °C for 7 hours 
 Wash the cells three times with PBS and add 2 ml/ well fresh growth media 
5. Isolation of mouse aortic endothelial cells (MAEC) 
(1) Cultrex® Basement Membrane Extract (BME) (R & D Systems) 
 Thaw BME at 2 – 8 °C on ice in a refrigerator overnight 
 Mix by slowly pipetting the solution up and down and be careful not to introduce air 
bubbles 
 Pipette 50 μl/cm2 (500 μl/ 35 mm dish) onto the growth surface 
 Place coated object at 37 °C for 30 minutes and coated objects are ready for use 
(2) Isolation of endothelial cells 
 Perfuse intracardially through the aorta using PBS and remove the ascending aorta 
 Remove adventitial tissue under a dissecting microscope 
 Cut the aorta into 3 µm long segments and rinse the segments with PBS 
 Place the segments on BME gel  
 Add 2 ml/ well of the endothelial cell growth media containing low-glucose DMEM 
supplemented with 15 % FBS, 180 µg/ml heparin and 20 µg/ml endothelial cell 
growth supplement 
 Change media every 2 days 
(3) MAEC extraction and cell culture 
 Thaw Dispase in water bath and equilibrate to 37 °C 
 Remove medium from cell culture 
 Add 0.2 ml/cm2 Dispase to dish using sterile technique (e.g. 2 ml/ 35 mm dish, 6 ml/ 
60 mm dish, 16 ml/ 100 mm dish) 
 Incubate at 37 °C for 2 hours to insure complete dissolution of the gel 
 Pipette mixture up and down to disperse cell suspension 
 Transfer mixture to sterile centrifuge tube 
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 Stop action of Dispase by dilution or chelation of Ca++ and Mg++ using 5 - 10 mM 
EDTA 
 Centrifuge cells at 1000 rpm, RT for 5 min and wash several times with PBS 
 Plate cells onto gelatin-coated dishes for 2 days in growth media containing D-valine 
to eliminate possible fibroblast contamination 
 Return endothelial cells after 2 days to growth medium without D-valine and grow 
cells to confluence 
 Test the purity of mouse endothelial cell cultures at passage 2 using either von 
Willebrand Factor staining or di-acetylated LDL uptake  
 Perform subsequent passages with Trypsin-EDTA 
6. Adhesion assay 
 Seed endothelial cells in the wells of a 6-well plate 24 hours before experiment 
 Maintain monocytes in suspension in 10 % FBS DMEM growth media  
 Fluorescently label monocytes (1x 107/ ml) in growth media containing 5 µg/ml 
Calcein-AM at 37 °C for 30 min 
 Pellet cells by centrifugation at 1000 rpm, RT for 5 min 
 Wash cell three times with PBS 
 Resuspend fluorescently labeled monocytes in endothelial cell growth media at 1x 
106 cells/ ml 
 Transfer 1 ml/ well monocyte dilutions onto endothelial cell monolayers 
 Bind at 37 °C for 30 min 
 Wash off unbound monocytes with PBS 
 Acquire images using fluorescent microscopy 
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Appendix B. Additional data 
 
Figure I. siRNA-mediated knock-down of NOR1 expression in endothelial cells 
Western Blotting for NOR1 expression in endothelial cells transfected with scrambled or 
NOR1 siRNA (50 nM) and treated with TNFα (1 ng/ml) for 6 h. 
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Figure II. The purity of mouse aortic endothelial cells (MAEC) at passage 2  
MAEC were cultured on coverglasses and immunostained for von Willebrand Factor (vWF) 
and smooth muscle α-actin (α-SMA) to identify endothelial cells and smooth muscle cells. 
Images were acquired using confocal microscopy (objective magnification x60). Stainings 
for vWF, α-SMA and Hoechst were merged into one image as indicated. The purity of 
MAEC at passage 2 was greater than 85 %. 
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